Patent Grant
11090195
Embodiments of the present invention relate to methods and apparatuses for dressing and treating a wound with topical negative pressure (TNP) therapy. In particular, but not exclusively, embodiments disclosed herein relate to a wound dressing for providing protection to a wound site, in which the wound dressing acts as a buffer to help prevent compression or shear forces exerted on the wound dressing, for example due to patient movement, from harming a healing wound. Embodiments of the wound dressing may act as a waste canister to collect and store wound exudate removed from a wound site, and also relate to the management of solid build-up in a wound dressing covering a wound site whilst TNP therapy is applied. Further, embodiments disclosed herein relate to a method and suction port for applying negative pressure to a wound dressing and a method of manufacturing a suction port and wound dressing.
Many different types of wound dressing are known for aiding in the healing process of a human or animal. These different types of wound dressing include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings.
In addition, TNP therapy, sometimes referred as vacuum assisted closure or negative pressure wound therapy, has recently been proposed as a successful mechanism for improving the healing rate of a wound. Such therapy is applicable to a broad range of wounds such as incisional wounds, open wounds and abdominal wounds or the like.
TNP therapy assists in the closure and healing of wounds by reducing tissue oedema; encouraging blood flow; stimulating the formation of granulation tissue; removing excess exudates and may reduce bacterial load and thus, infection to the wound. Furthermore, TNP therapy permits less outside disturbance of the wound and promotes more rapid healing.
During TNP therapy, a suction source such as a vacuum pump or the like is utilized to create a negative pressure region. That is to say, a region where an experienced pressure is below that of the surroundings. Wound exudate and other potentially harmful material is extracted from the wound region and must be stored for later disposal. A problem associated with many known techniques is that a separate canister must be provided for storage of such exudate. Provision of such canisters is costly and bulky and prone to failure.
A proposal has been suggested to store extracted wound exudate in the wound dressing itself that is used to cover a wound site and create the wound chamber region where negative pressure is established. However, it is known that many different wound types can exude high flow rates of exudate and therefore storage of exuding material in a wound dressing can be problematical since the wound dressing will only have a limited capacity for fluid uptake before a dressing change is required. This can limit a time of use between dressing changes and can prove costly if many wound dressings are required to treat a given wound.
It has been suggested as a solution to this problem, that a liquid impermeable moisture vapor permeable cover layer can be utilized as an uppermost cover layer for the wound dressing. The air impermeable nature of the cover layer provides a sealing layer over the wound site so that negative pressure can be established below the dressing in the region of the wound. The moisture vapor permeability of this covering layer is selected so that liquid can constantly evaporate away from the top of the dressing. This means that as therapy is continued the dressing does not have to take up and hold all liquid exuding from the wound. Rather, some liquid is constantly escaping in the form of moisture vapor from the upper environs of the dressing.
Whilst such dressings work well in practice, the continuous evaporation of moisture vapor from the dressing can lead to the problem of crust formation in the dressing. That is to say, because of the continuous drawing of liquid away from the wound site solid particulate matter is more prone to formation and accumulation in the dressing. Under certain circumstances the build-up of such solid material can lead to blockages forming in the wound dressing in the flowpath between the wound and the source of negative pressure. This can potentially cause problems in that therapy may need to be halted to change a dressing if the blockages reach a critical level.
Further, there is much prior art available relating to the provision of apparatuses and methods of use thereof for the application of TNP therapy to wounds together with other therapeutic processes intended to enhance the effects of the TNP therapy.
It will be appreciated that from time to time accidents may happen to patients undergoing negative pressure wound therapy. Such accidents might cause short term or long term forces to be applied to a dressing covering a wound. Alternatively patient movement may bring the patient and any dressing covering a healing wound into contact with an external object. In such occurrences compressive forces or lateral forces may occur. Such force can cause disturbance of a wound bed which can damage a wound site. A particular cause for concern is during the treatment of skin graft wounds. Under such conditions lateral forces can entirely upset or tear apart a healing skin graft region.
It is an aim of certain embodiments of the present invention to at least partly mitigate the above-mentioned problems.
It is an aim of certain embodiments of the present invention to provide a method for providing negative pressure at a wound site to aid in wound closure and healing in which wound exudate drawn from a wound site during the therapy is collected and stored in a wound dressing.
It is an aim of certain embodiments of the present invention to provide a wound dressing having an increased capacity for absorbing wound exudate reducing the frequency with which the dressings must be changed.
It is further an aim of certain embodiments of the invention to manage the movement of wound exudate through a dressing to avoid blockages occurring that lead to reduced life of the dressing.
It is an aim of certain embodiments of the present invention to provide a wound dressing having an increased capacity to absorb compressive forces exerted on the wound dressing.
It is an aim of certain embodiments of the present invention to provide a wound dressing having an increased capacity to prevent shear forces from an outer surface of a wound dressing from being translated into corresponding shear forces at a wound site.
It is an aim of certain embodiments of the present invention to provide a wound dressing which can “give” in a direction perpendicular to and parallel to a wound site surface even when the dressing experiences negative pressure.
It is an aim of certain embodiments of the present invention to provide a wound dressing able to be used with topical negative pressure therapy which helps maintain an open flow path so that therapy can be continued unhindered by blockages caused by build-up of solid matter.
It is an aim of certain embodiments of the present invention to provide a method and apparatus for treating a wound with topical negative pressure therapy by preventing blockage of a flowpath region of a wound dressing.
Embodiments disclosed herein are directed toward the treatment of wounds with TNP. In particular, certain embodiments disclose a wound dressing capable of absorbing and storing wound exudate in conjunction with a pump, for example a miniaturized pump. Some wound dressing embodiments further comprise a transmission layer configured to transmit wound exudates to an absorbent layer disposed in the wound dressing. Additionally, some embodiments provide for a port or other fluidic connector configured to retain wound exudate within the wound dressing while transmitting negative pressure to the wound dressing.
According to a first embodiment of the present invention there is provided a wound treatment apparatus comprising: a wound dressing comprising:
According to a second embodiment of the present invention there is provided a method for the treatment of a wound comprising:
According to a another embodiment of the present invention there is provided a wound dressing for providing protection at a wound site, comprising:
According to a one embodiment of the present invention there is provided a method for providing protection at a wound site, comprising:
and
According to another embodiment of the present invention there is provided an apparatus for dressing a wound for the application of topical negative pressure at a wound site, comprising:
According to a further embodiment of the present invention there is provided a method of applying TNP at a wound site, comprising the steps of:
According to an additional embodiment of the present invention there is provided apparatus for dressing a wound for the application of topical negative pressure at a wound site, comprising:
According to another embodiment of the present invention there is provided a method of applying TNP at a wound site, comprising the steps of:
According to still another embodiment of the present invention there is provided apparatus for dressing a wound for the application of topical negative pressure at a wound site, comprising:
According to an additional embodiment of the present invention there is provided a method of applying TNP at a wound site, comprising the steps of:
According to one embodiment of the present invention there is provided a suction port for applying negative pressure to a wound dressing for the application of topical negative pressure at a wound site, the suction port comprising:
According to an additional embodiment of the present invention there is provided a method of communicating negative pressure to a wound dressing for the application of topical negative pressure at a wound site, comprising the steps of:
According to another embodiment of the invention there is provided a method of manufacturing a suction port for applying negative pressure to a wound dressing for the application of topical negative pressure at a wound site, the suction port having a connector portion for connecting the suction port to a source of negative pressure and a sealing surface for sealing the suction port to a cover layer of a wound dressing, the method comprising:
According to yet another embodiment of the present invention there is provided apparatus for the application of TNP therapy to a wound site, comprising:
According to still another embodiment of the present invention there is provided a method of applying TNP therapy to a wound site, comprising:
Certain embodiments provide a wound dressing which even when under negative pressure conditions is able to provide further “give” to buffer compression forces from harming a wound.
Certain embodiments provide a wound dressing able to disconnect shear forces applied to the dressing from the wound site covered by the dressing. As a result damage to the wound can be wholly or at least partially avoided.
Certain embodiments provide the advantage that a wound site can be covered with a wound dressing which is simultaneously able to deliver negative pressure wound therapy to a wound site, collect exudate and provide protection from forces operating on the dressing.
Certain embodiments provide the advantage that forces operating on a dressing can be offset by dissipating loads operating over a relatively small distance on an upper layer of the dressing to a relatively larger area on a lower surface of the dressing. The force is thus dissipated over a larger area thus reducing the effect of the force.
Certain embodiments provide the advantage that a wound dressing can be used to collect wound exudate generated during a negative pressure therapy process, whilst extending the useful lifetime of the dressing by transpiring a water component of the wound exudate. A pump remote from the wound dressing can be connected to the wound dressing and reused whilst the wound dressing itself is used to collect wound exudate and may then be disposed of after use.
Certain embodiments provide a wound dressing and/or method of applying topical negative pressure in which a flowpath through a wound dressing is kept open so that therapy can be continued for as long as desired by a care giver.
Certain embodiments prevent solid material, which may cause a blockage, from entering a flowpath region in the wound dressing by using a layer of the dressing to act as a bar to such material.
Certain embodiments prevent build-up of solid material in a flowpath region of a wound dressing by ensuring that any solid material that enters into that flowpath region can always escape into a further region of the dressing.
Certain embodiments provide the advantage that the build-up of solid material in a flowpath in a wound dressing is avoided by having an absorbent layer close to the flowpath region store liquid over time. This helps keep the environment of the flowpath region moist which helps avoid crusting.
Certain embodiments provide the advantage that a wound dressing can be used to collect wound exudate generated during a negative pressure therapy process, whilst extending the useful lifetime of the dressing by transpiring a water component of the wound exudate. A pump remote from the wound dressing can be connected to the wound dressing and reused whilst the wound dressing itself is used to collect wound exudate and may then be disposed of after use.
Embodiments of the present invention will now be described hereinafter, by way of example only, with reference to the accompanying drawings in which:
In the drawings like reference numerals refer to like parts.
The wound dressing 100 can be located over a wound site to be treated. The dressing 100 forms a sealed cavity over the wound site. It will be appreciated that throughout this specification reference is made to a wound. In this sense it is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, incisions, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like.
In some embodiments, it may be preferable for the wound site to be filled partially or completely with a wound packing material. This wound packing material is optional, but may be desirable in certain wounds, for example deeper wounds. The wound packing material can be used in addition to the wound dressing 100. The wound packing material generally may comprise a porous and conformable material, for example foam (including reticulated foams), and gauze. Preferably, the wound packing material is sized or shaped to fit within the wound site so as to fill any empty spaces. The wound dressing 100 may then be placed over the wound site and wound packing material overlying the wound site. When a wound packing material is used, once the wound dressing 100 is sealed over the wound site, TNP is transmitted from a pump through the wound dressing 100, through the wound packing material, and to the wound site. This negative pressure draws wound exudate and other fluids or secretions away from the wound site.
It is envisaged that the negative pressure range for the apparatus embodying the present invention may be between about −20 mmHg and −200 mmHg (note that these pressures are relative to normal ambient atmospheric pressure thus, −200 mmHg would be about 560 mmHg in practical terms). In one embodiment, the pressure range may be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg could be used. Alternatively a pressure range of over −100 mmHg could be used or over −150 mmHg.
It will be appreciated that according to certain embodiments of the present invention the pressure provided may be modulated over a period of time according to one or more desired and predefined pressure profiles. For example such a profile may include modulating the negative pressure between two predetermined negative pressures P1 and P2 such that pressure is held substantially constant at P1 for a pre-determined time period T1 and then adjusted by suitable means such as varying pump work or restricting fluid flow or the like, to a new predetermined pressure P2 where the pressure may be held substantially constant for a further predetermined time period T2. Two, three or four or more predetermined pressure values and respective time periods may be optionally utilized. Other embodiments may employ more complex amplitude/frequency wave forms of pressure flow profiles may also be provided e.g. sinusoidal, sore tooth, systolic-diastolic or the like.
As illustrated in
A layer 105 of porous material is located above the wound contact layer. This porous layer, or transmission layer, 105 allows transmission of fluid including liquid and gas away from a wound site into upper layers of the wound dressing. In particular, the transmission layer 105 ensures that an open air channel can be maintained to communicate negative pressure over the wound area even when the absorbent layer has absorbed substantial amounts of exudates. The layer should remain open under the typical pressures that will be applied during negative pressure wound therapy as described above, so that the whole wound site sees an equalized negative pressure. The layer 105 is formed of a material having a three dimensional structure. For example, a knitted or woven spacer fabric (for example Baltex 7970 weft knitted polyester) or a non-woven fabric could be used. Other materials could of course be utilized, and examples of such materials are described below with respect to
In some embodiments, the transmission layer comprises a 3D polyester spacer fabric layer including a top layer (that is to say, a layer distal from the wound-bed in use) which is a 84/144 textured polyester, and a bottom layer (that is to say, a layer which lies proximate to the wound bed in use) which is a 100 denier flat polyester and a third layer formed sandwiched between these two layers which is a region defined by a knitted polyester viscose, cellulose or the like monofilament fiber. Other materials and other linear mass densities of fiber could of course be used.
Whilst reference is made throughout this disclosure to a monofilament fiber it will be appreciated that a multistrand alternative could of course be utilized.
The top spacer fabric thus has more filaments in a yarn used to form it than the number of filaments making up the yarn used to form the bottom spacer fabric layer.
This differential between filament counts in the spaced apart layers helps control moisture flow across the transmission layer. Particularly, by having a filament count greater in the top layer, that is to say, the top layer is made from a yarn having more filaments than the yarn used in the bottom layer, liquid tends to be wicked along the top layer more than the bottom layer. In use, this differential tends to draw liquid away from the wound bed and into a central region of the dressing where the absorbent layer helps lock the liquid away or itself wicks the liquid onwards towards the cover layer where it can be transpired.
Preferably, to improve the liquid flow across the transmission layer (that is to say perpendicular to the channel region formed between the top and bottom spacer layers, the 3D fabric is treated with a dry cleaning agent (such as, but not limited to, Perchloro Ethylene) to help remove any manufacturing products such as mineral oils, fats and/or waxes used previously which might interfere with the hydrophilic capabilities of the transmission layer. In some embodiments, an additional manufacturing step can subsequently be carried in which the 3D spacer fabric is washed in a hydrophilic agent (such as, but not limited to, Feran Ice 30 g/l available from the Rudolph Group). This process step helps ensure that the surface tension on the materials is so low that liquid such as water can enter the fabric as soon as it contacts the 3D knit fabric. This also aids in controlling the flow of the liquid insult component of any exudates.
A layer 110 of absorbent material is provided above the transmission layer 105. The absorbent material which may be a foam or non-woven natural or synthetic material and which may optionally include or be super-absorbent material forms a reservoir for fluid, particularly liquid, removed from the wound site and draws those fluids towards a cover layer 140. The material of the absorbent layer also prevents liquid collected in the wound dressing from flowing in a sloshing manner. The absorbent layer 110 also helps distribute fluid throughout the layer via a wicking action so that fluid is drawn from the wound site and stored throughout the absorbent layer. This helps prevent agglomeration in areas of the absorbent layer. The capacity of the absorbent material must be sufficient to manage the exudates flow rate of a wound when negative pressure is applied. Since in use the absorbent layer experiences negative pressures the material of the absorbent layer is chosen to absorb liquid under such circumstances. A number of materials exist that are able to absorb liquid when under negative pressure, for example superabsorber material. The absorbent layer 110 may typically be manufactured from ALLEVYN™ foam, Freudenberg 114-224-4 and/or Chem-Posite™ 11C-450.
In some embodiments, the absorbent layer is a layer of non-woven cellulose fibers having super-absorbent material in the form of dry particles dispersed throughout. Use of the cellulose fibers introduces fast wicking elements which help quickly and evenly distribute liquid taken up by the dressing. The juxtaposition of multiple strand-like fibers leads to strong capillary action in the fibrous pad which helps distribute liquid. In this way, the super-absorbent material is efficiently supplied with liquid. Also, all regions of the absorbent layer are provided with liquid.
The wicking action also assists in bringing liquid into contact with the upper cover layer to aid increase transpiration rates of the dressing.
The wicking action also assists in delivering liquid downwards towards the wound bed when exudation slows or halts. This delivery process helps maintain the transmission layer and lower wound bed region in a moist state which helps prevent crusting within the dressing (which could lead to blockage) and helps maintain an environment optimized for wound healing.
In some embodiments, the absorbent layer may be an air-laid material. Heat fusible fibers may optionally be used to assist in holding the structure of the pad together. It will be appreciated that rather than using super-absorbing particles or in addition to such use, super-absorbing fibers may be utilized according to certain embodiments of the present invention. An example of a suitable material is the Product Chem-Posite™ 11 C available from Emerging Technologies Inc (ETi) in the USA.
Optionally, according to certain embodiments of the present invention, the absorbent layer may include synthetic stable fibers and/or bi-component stable fibers and/or natural stable fibers and/or super-absorbent fibers. Fibers in the absorbent layer may be secured together by latex bonding or thermal bonding or hydrogen bonding or a combination of any bonding technique or other securing mechanism. In some embodiments, the absorbent layer is formed by fibers which operate to lock super-absorbent particles within the absorbent layer. This helps ensure that super-absorbent particles do not move external to the absorbent layer and towards an underlying wound bed. This is particularly helpful because when negative pressure is applied there is a tendency for the absorbent pad to collapse downwards and this action would push super-absorbent particle matter into a direction towards the wound bed if they were not locked away by the fibrous structure of the absorbent layer.
The absorbent layer may comprise a layer of multiple fibers. Preferably, the fibers are strand-like and made from cellulose, polyester, viscose or the like. Preferably, dry absorbent particles are distributed throughout the absorbent layer ready for use. In some embodiments, the absorbent layer comprises a pad of cellulose fibers and a plurality of super absorbent particles. In additional embodiments, the absorbent layer is a non-woven layer of randomly orientated cellulose fibers.
Super-absorber particles/fibers may be, for example, sodium polyacrylate or carbomethoxycellulose materials or the like or any material capable of absorbing many times its own weight in liquid. In some embodiments, the material can absorb more than five times its own weight of 0.9% W/W saline, etc. In some embodiments, the material can absorb more than 15 times its own weight of 0.9% W/W saline, etc. In some embodiments, the material is capable of absorbing more than 20 times its own weight of 0.9% W/W saline, etc. Preferably, the material is capable of absorbing more than 30 times its own weight of 0.9% W/W saline, etc.
Preferably, the particles of superabsorber are very hydrophilic and grab the fluid as it enters the dressing, swelling up on contact. An equilibrium is set up within the dressing core whereby moisture passes from the superabsorber into the dryer surrounding area and as it hits the top film the film switches and the fluid vapor starts to be transpired. A moisture gradient is established within the dressing to continually remove fluid from the wound bed and ensure the dressing does not become heavy with exudate.
Preferably the absorbent layer includes at least one through hole located so as to underly the suction port. As illustrated in
Where an opening is provided in the absorbent layer the thickness of the layer itself will act as a stand-off separating any overlying layer from the upper surface (that is to say the surface facing away from a wound in use) of the transmission layer 105. An advantage of this is that the filter of the port is thus decoupled from the material of the transmission layer. This helps reduce the likelihood that the filter will be wetted out and thus will occlude and block further operation.
Use of one or more through holes in the absorption layer also has the advantage that during use if the absorbent layer contains a gel forming material, such as superabsorber, that material as it expands to absorb liquid, does not form a barrier through which further liquid movement and fluid movement in general cannot pass. In this way each opening in the absorbent layer provides a fluid pathway between the transmission layer directly to the wound facing surface of the filter and then onwards into the interior of the port.
A gas impermeable, but moisture vapor permeable, cover layer 140 extends across the width of the wound dressing. The cover layer, which may for example be a polyurethane film (for example, Elastollan SP9109) having a pressure sensitive adhesive on one side, is impermeable to gas and this layer thus operates to cover the wound and to seal a wound cavity over which the wound dressing is placed. In this way an effective chamber is made between the cover layer and a wound site where a negative pressure can be established. The cover layer 140 is sealed to the wound contact layer 102 in a border region 200 around the circumference of the dressing, ensuring that no air is drawn in through the border area, for example via adhesive or welding techniques. The cover layer 140 protects the wound from external bacterial contamination (bacterial barrier) and allows liquid from wound exudates to be transferred through the layer and evaporated from the film outer surface. The cover layer 140 typically comprises two layers; a polyurethane film and an adhesive pattern spread onto the film. The polyurethane film is moisture vapor permeable and may be manufactured from a material that has an increased water transmission rate when wet.
The absorbent layer 110 may be of a greater area than the transmission layer 105, such that the absorbent layer overlaps the edges of the transmission layer 105, thereby ensuring that the transmission layer does not contact the cover layer 140. This provides an outer channel 115 of the absorbent layer 110 that is in direct contact with the wound contact layer 102, which aids more rapid absorption of exudates to the absorbent layer. Furthermore, this outer channel 115 ensures that no liquid is able to pool around the circumference of the wound cavity, which may otherwise seep through the seal around the perimeter of the dressing leading to the formation of leaks.
In order to ensure that the air channel remains open when a vacuum is applied to the wound cavity, the transmission layer 105 must be sufficiently strong and non-compliant to resist the force due to the pressure differential. However, if this layer comes into contact with the relatively delicate cover layer 140, it can cause the formation of pin-hole openings in the cover layer 140 which allow air to leak into the wound cavity. This may be a particular problem when a switchable type polyurethane film is used that becomes weaker when wet. The absorbent layer 110 is generally formed of a relatively soft, non-abrasive material compared to the material of the transmission layer 105 and therefore does not cause the formation of pin-hole openings in the cover layer. Thus by providing an absorbent layer 110 that is of greater area than the transmission layer 105 and that overlaps the edges of the transmission layer 105, contact between the transmission layer and the cover layer is prevented, avoiding the formation of pin-hole openings in the cover layer 140.
The absorbent layer 110 is positioned in fluid contact with the cover layer 140. As the absorbent layer absorbs wound exudate, the exudate is drawn towards the cover layer 140, bringing the water component of the exudate into contact with the moisture vapor permeable cover layer. This water component is drawn into the cover layer itself and then evaporates from the top surface of the dressing. In this way, the water content of the wound exudate can be transpired from the dressing, reducing the volume of the remaining wound exudate that is to be absorbed by the absorbent layer 110, and increasing the time before the dressing becomes full and must be changed. This process of transpiration occurs even when negative pressure has been applied to the wound cavity, and it has been found that the pressure difference across the cover layer when a negative pressure is applied to the wound cavity has negligible impact on the moisture vapor transmission rate across the cover layer.
An orifice 145 is provided in the cover film 140 to allow a negative pressure to be applied to the dressing 100. A suction port 150 is sealed to the top of the cover film 140 over the orifice 145, and communicates negative pressure through the orifice 145. A length of tubing 220 may be coupled at a first end to the suction port 150 and at a second end to a pump unit (not shown) to allow fluids to be pumped out of the dressing. The port may be adhered and sealed to the cover film 140 using an adhesive such as an acrylic, cyanoacrylate, epoxy, UV curable or hot melt adhesive. The port 150 is formed from a soft polymer, for example a polyethylene, a polyvinyl chloride, a silicone or polyurethane having a hardness of 30 to 90 on the Shore A scale.
An aperture or through-hole 146 is provided in the absorbent layer 110 beneath the orifice 145 such that the orifice is connected directly to the transmission layer 105. This allows the negative pressure applied to the port 150 to be communicated to the transmission layer 105 without passing through the absorbent layer 110. This ensures that the negative pressure applied to the wound site is not inhibited by the absorbent layer as it absorbs wound exudates. In other embodiments, no aperture may be provided in the absorbent layer 110, or alternatively a plurality of apertures underlying the orifice 145 may be provided.
As shown in
A filter element 130 that is impermeable to liquids, but permeable to gases is provided to act as a liquid barrier, and to ensure that no liquids are able to escape from the wound dressing. The filter element may also function as a bacterial barrier. Typically the pore size is 0.2 μm. Suitable materials for the filter material of the filter element 130 include 0.2 micron Gore™ expanded PTFE from the MMT range, PALL Versapore™ 200R, and Donaldson™ TX6628. Larger pore sizes can also be used but these may require a secondary filter layer to ensure full bioburden containment. As wound fluid contains lipids it is preferable, though not essential, to use an oleophobic filter membrane for example 1.0 micron MMT-332 prior to 0.2 micron MMT-323. This prevents the lipids from blocking the hydrophobic filter. The filter element can be attached or sealed to the port and/or the cover film 140 over the orifice 145. For example, the filter element 130 may be molded into the port 150, or may be adhered to both the top of the cover layer 140 and bottom of the port 150 using an adhesive such as, but not limited to, a UV cured adhesive.
It will be understood that other types of material could be used for the filter element 130. More generally a microporous membrane can be used which is a thin, flat sheet of polymeric material, this contains billions of microscopic pores. Depending upon the membrane chosen these pores can range in size from 0.01 to more than 10 micrometers. Microporous membranes are available in both hydrophilic (water filtering) and hydrophobic (water repellent) forms. In some embodiments of the invention, filter element 130 comprises a support layer and an acrylic co-polymer membrane formed on the support layer. Preferably the wound dressing 100 according to certain embodiments of the present invention uses microporous hydrophobic membranes (MHMs). Numerous polymers may be employed to form MHMs. For example, PTFE, polypropylene, PVDF and acrylic copolymer. All of these optional polymers can be treated in order to obtain specific surface characteristics that can be both hydrophobic and oleophobic. As such these will repel liquids with low surface tensions such as multi-vitamin infusions, lipids, surfactants, oils and organic solvents.
MHMs block liquids whilst allowing air to flow through the membranes. They are also highly efficient air filters eliminating potentially infectious aerosols and particles. A single piece of MHM is well known as an option to replace mechanical valves or vents. Incorporation of MHMs can thus reduce product assembly costs improving profits and costs/benefit ratio to a patient.
The filter element 130 may also include an odor absorbent material, for example activated charcoal, carbon fiber cloth or Vitec Carbotec-RT Q2003073 foam, or the like. For example, an odor absorbent material may form a layer of the filter element 130 or may be sandwiched between microporous hydrophobic membranes within the filter element.
The filter element 130 thus enables gas to be exhausted through the orifice 145. Liquid, particulates and pathogens however are contained in the dressing.
In
In particular for embodiments with a single port 150 and through hole, it may be preferable for the port 150 and through hole to be located in an off-center position as illustrated in
According to some embodiments, the filter element 130 forms part of the bacterial barrier over the wound site, and therefore it is important that a good seal is formed and maintained around the filter element. However, it has been determined that a seal formed by adhering the filter element 130 to the cover layer 140 is not sufficiently reliable. This is a particular problem when a moisture vapor permeable cover layer is used, as the water vapor transpiring from the cover layer 140 can affect the adhesive, leading to breach of the seal between the filter element and the cover layer. Thus, according to some embodiments of the invention an alternative arrangement for sealing the filter element 130 to stop liquid from entering the connector portion 154 is employed.
By providing the filter element 130 as part of the suction port 150, as illustrated in
While the suction port 150 has been described in the context of the wound dressing 100 of
The wound dressing 100 and its methods of manufacture and use as described herein may also incorporate features, configurations and materials described in the following patents and patent applications incorporated by reference in their entireties: U.S. Pat. Nos. 7,524,315, 7,708,724, and 7,909,805; U.S. Patent Application Publication Nos. 2005/0261642, 2007/0167926, 2009/0012483, 2009/0254054, 2010/0160879, 2010/0160880, 2010/0174251, 2010/0274207, 2010/0298793, 2011/0009838, 2011/0028918, 2011/0054421, and 2011/0054423; as well as U.S. application Ser. No. 12/941,390, filed Nov. 8, 2010, Ser. No. 29/389,782, filed Apr. 15, 2011, and Ser. No. 29/389,783, filed Apr. 15, 2011. From these incorporated by reference patents and patent applications, features, configurations, materials and methods of manufacture or use for similar components to those described in the present disclosure may be substituted, added or implemented into embodiments of the present application.
In operation the wound dressing 100 is sealed over a wound site forming a wound cavity. A pump unit (illustrated in
Turning to
The wound dressing 100 may be sized as necessary for the size and type of wound it will be used in. In some embodiments, the wound dressing 100 may measure between 20 and 40 cm on its long axis, and between 10 to 25 cm on its short axis. For example, dressings may be provided in sizes of 10×20 cm, 10×30 cm, 10×40 cm, 15×20 cm, and 15×30 cm. In some embodiments, the wound dressing 100 may be a square-shaped dressing with sides measuring between 15 and 25 cm (e.g., 15×15 cm, 20×20 cm and 25×25 cm). The absorbent layer 110 may have a smaller area than the overall dressing, and in some embodiments may have a length and width that are both about 3 to 10 cm shorter, more preferably about 5 cm shorter, than that of the overall dressing 100. In some rectangular-shape embodiments, the absorbent layer 110 may measure between 10 and 35 cm on its long axis, and between 5 and 10 cm on its short axis. For example, absorbent layers may be provided in sizes of 5.6×15 cm or 5×10 cm (for 10×20 cm dressings), 5.6×25 cm or 5×20 cm (for 10×30 cm dressings), 5.6×35 cm or 5×30 cm (for 10×40 cm dressings), 10×15 cm (for 15×20 cm dressings), and 10×25 cm (for 15×30 cm dressings). In some square-shape embodiments, the absorbent layer 110 may have sides that are between 10 and 20 cm in length (e.g., 10×10 cm for a 15×15 cm dressing, 15×15 cm for a 20×20 cm dressing, or 20×20 cm for a 25×25 cm dressing). The transmission layer 105 is preferably smaller than the absorbent layer, and in some embodiments may have a length and width that are both about 0.5 to 2 cm shorter, more preferably about 1 cm shorter, than that of the absorbent layer. In some rectangular-shape embodiments, the transmission layer may measure between 9 and 34 cm on its long axis and between 3 and 5 cm on its short axis. For example, transmission layers may be provided in sizes of 4.6×14 cm or 4×9 cm (for 10×20 cm dressings), 4.6×24 cm or 4×19 cm (for 10×30 cm dressings), 4.6×34 cm or 4×29 cm (for 10×40 cm dressings), 9×14 cm (for 15×20 cm dressings), and 9×24 cm (for 15×30 cm dressings). In some square-shape embodiments, the transmission layer may have sides that are between 9 and 19 cm in length (e.g., 9×9 cm for a 15×15 cm dressing, 14×14 cm for a 20×20 cm dressing, or 19×19 cm for a 25×25 cm dressing).
It will be understood that according to embodiments of the present invention the wound contact layer is optional. This layer is, if used, porous to water and faces an underlying wound site. A transmission layer 105 such as an open celled foam, or a knitted or woven spacer fabric is used to distribute gas and fluid removal such that all areas of a wound are subjected to equal pressure. The cover layer together with the filter layer forms a substantially liquid tight seal over the wound. Thus when a negative pressure is applied to the port 150 the negative pressure is communicated to the wound cavity below the cover layer. This negative pressure is thus experienced at the target wound site. Fluid including air and wound exudate is drawn through the wound contact layer and transmission layer 105. The wound exudate drawn through the lower layers of the wound dressing is dissipated and absorbed into the absorbent layer 110 where it is collected and stored. Air and moisture vapor is drawn upwards through the wound dressing through the filter layer and out of the dressing through the suction port. A portion of the water content of the wound exudate is drawn through the absorbent layer and into the cover layer 140 and then evaporates from the surface of the dressing.
As discussed above, when a negative pressure is applied to a wound dressing sealed over a wound site, fluids including wound exudate are drawn from the wound site and through the transmission layer 105 towards the orifice 145. Wound exudate is then drawn into the absorbent layer 110 where it is absorbed. However, some wound exudate may not be absorbed and may move to the orifice 145. Filter element 130 provides a barrier that stops any liquid in the wound exudate from entering the connection portion 154 of the suction port 150. Therefore, unabsorbed wound exudate may collect underneath the filter element 130. If sufficient wound exudate collects at the filter element, a layer of liquid will form across the surface of filter element 130 and the filter element will become blocked as the liquid cannot pass through the filter element 130 and gases will be stopped from reaching the filter element by the liquid layer. Once the filter element becomes blocked, negative pressure can no longer be communicated to the wound site, and the wound dressing must be changed for a fresh dressing, even though the total capacity of the absorbent layer has not been reached.
In a preferred embodiment, the port 150, along with any aperture 146 in the absorbing layer 110 situated below it, generally aligns with the mid-longitudinal axis A-A illustrated in
Certain orientations of the wound dressing may increase the likelihood of the filter element 130 becoming blocked in this way, as the movement of the wound exudate through the transmission layer may be aided by the effect of gravity. Thus, if due to the orientation of the wound site and wound dressing, gravity acts to increase the rate at which wound exudate is drawn towards the orifice 145, the filter may become blocked with wound exudate more quickly. Thus, the wound dressing would have to be changed more frequently and before the absorbent capacity of the absorbent layer 110 has been reached.
In order to avoid the premature blocking of the wound dressing 100 by wound exudate drawn towards the orifice 145 some embodiments of the invention include at least one element configured to reduce the rate at which wound exudate moves towards the orifice 145. The at least one element may increase the amount of exudate that is absorbed into the absorbent layer before reaching the orifice 145 and/or may force the wound exudate to follow a longer path through the dressing before reaching the orifice 145, thereby increasing the time before the wound dressing becomes blocked.
Embodiments of baffle elements that may be used in the wound dressing described herein are preferably at least partly flexible, so as to permit the wound dressing to flex and conform with the skin of the patient surrounding the wound site. When so present in the wound dressing, the baffle elements are preferably constructed so as to at least partially prevent liquid from flowing directly to the wound dressing port or orifice and its associated filter, if so provided. The baffle elements thus increase the distance that liquids may require to reach the port, which may help in absorbing these fluids into the absorbent or superabsorbent material of the wound dressing.
According to some embodiments of the invention, the baffle element may comprise a sealing region in which the absorbent layer 110 and transmission layer 105 are absent and cover layer 140 is sealed to the wound contact layer 101. Thus, the baffle element presents a barrier to the motion of the wound exudate, which must therefore follow a path that avoids the baffle element. Thus the time taken for the wound exudate to reach the orifice is increased.
In some embodiments, the baffle elements may be an insert of a substantially non-porous material, for example a closed-cell polyethylene foam, placed inside the dressing. In some cases, it may be preferable to place such an inserted baffle element in a sealing region where one or more of the absorbent layer 110 and/or transmission layer 105 are absent. A sealant, for example a viscous curing sealant such as a silicone sealant, could be placed or injected as a thin strip so as to form a baffle element that is substantially liquid impermeable. Such a baffle element could be placed or injected into a region of the transmission layer 105 and/or absorbent layer 110, or also a sealing region where the absorbent layer 110 and/or transmission layer 105 are absent.
The embodiments of
Alternatively, or additionally, baffle elements may comprise one or more channels provided in the surface of the transmission layer 105 underlying and abutting the absorbent layer 110. In use, when negative pressure is applied to the wound dressing, the absorbent layer 110 will be drawn into the channel. The channel in the transmission layer may have a depth substantially equal to the depth of the transmission layer, or may have a depth less than the depth of the transmission layer. The dimensions of the channel may be chosen to ensure that the channel is filled by the absorbent layer 110 when negative pressure is applied to the wound dressing. According to some embodiments, the channel in the transmission layer comprises a channel of absorbent material in the transmission layer 105.
The baffle elements may be formed into a range of shapes and patterns, for example
According to some embodiments of the invention, the at least one element comprises an array of vias, or troughs, in the transmission layer 105.
When negative pressure is applied to the wound dressing, the absorbent layer 110 is drawn into the vias 210, increasing the area of the absorbent layer that comes into contact with wound exudate being drawn through the transmission layer 105. Alternatively, the vias 210 may be filled with further absorbent material for absorbing wound exudate being drawn through the transmission layer 105. The vias may extend through the depth of the transmission layer 105, or may extend through only part of the transmission layer.
Wound exudate moving through the transmission layer 105 under the influence of gravity will fall through the transmission layer in a substantially linear manner. Any such linear pathways will, at some point, intersect with one of the vias 210, and thus the exudate will be brought into contact with absorbent material within the vias 210. Wound exudate coming into contact with absorbent material will be absorbed, stopping the flow of the wound exudate through the transmission layer 105, and reducing the amount of unabsorbed wound exudate that may otherwise pool around the orifice. It will be appreciated that the vias are not limited to diamond shapes, and that any pattern of vias may be used. Preferably, the vias will be arranged to ensure that all linear paths through the transmission layer 105 intersect with at least one via. The pattern of vias may be chosen to minimize the distance that wound exudate is able to travel though the transmission layer before encountering a via and being absorbed.
In use, wound exudate is drawn towards the orifice 145 by the application of negative pressure at the suction port 150. However, the air channel 710 present a relatively long serpentine path to be followed by the wound exudate before it reaches the orifice 145. This long path increases the time that negative pressure can be applied to the dressing before wound exudate traverses the distance between the transmission layer and the orifice and blocks the filter element 130, thereby increasing the time the dressing can be in use before it must be replaced.
The wound dressing shown in
Further embodiments of the invention may comprise greater numbers of air channels connecting the transmission layer 105 to the orifice.
According to some embodiments of the invention, two or more orifices may be provided in the cover layer 140 for applying the negative pressure to the wound dressing. The two or more orifices can be distributed across the cover layer 140 such that if one orifice becomes blocked by wound exudate due to the wound dressing being in a particular orientation, at least one remaining orifice would be expected to remain unblocked. Each orifice is in fluid communication with a wound chamber defined by the wound dressing, and is therefore able to communicate the negative pressure to the wound site.
In use, the wound dressing having two orifices is sealed over a wound site to form a wound cavity and an external source of negative pressure is applied to one of the orifices 145, 845, and the negative pressure will be communicated to the remaining orifice via the fluid communication passage. Thus, the negative pressure is communicated via the two orifices 145, 845 to the transmission layer 105, and thereby to the wound site. If one of the orifices 145, 845 becomes blocked due to wound exudate collecting at the orifice under the influence of gravity, the remaining orifice should remain clear, allowing negative pressure to continue to be communicated to the wound site. According to some embodiments, the transmission layer 105 may be omitted, and the two orifices will communicate the negative pressure to the wound site via the absorbent layer 110.
According to some embodiments, a single filter element may be used extending underneath the length of the fluid communication passage and the two orifices. While the above example embodiment has been described as having two orifices, it will be understood that more than two orifices could be used, the fluid communication passage allowing the negative pressure to be communicated between the orifices.
In use, the wound dressing is sealed over a wound site to form a wound cavity and an external source of negative pressure is applied to the orifice. If, due to the orientation of the wound dressing, wound exudate moves under the influence of gravity to collect around one end 355 of the orifice 350, a portion of the orifice 350 near to the end 355 will become blocked. However, a portion of the orifice near to the remaining end 356 should remain clear, allowing continued application of negative pressure to the wound site.
As still further options the dressing can contain anti-microbial e.g. nanocrystalline silver agents on the wound contact layer and/or silver sulphur diazine in the absorbent layer. These may be used separately or together. These respectively kill micro-organisms in the wound and micro-organisms in the absorption matrix. As a still further option other active components, for example, pain suppressants, such as ibuprofen, may be included. Also agents which enhance cell activity, such as growth factors or that inhibit enzymes, such as matrix metalloproteinase inhibitors, such as tissue inhibitors of metalloproteinase (TIMPS) or zinc chelators could be utilized. As a still further option odor trapping elements such as activated carbon, cyclodextrine, zeolite or the like may be included in the absorbent layer or as a still further layer above the filter layer.
Throughout this specification reference will be made to a relaxed mode of operation and a forced mode of operation. It is to be understood that the relaxed mode of operation corresponds to a natural state of the material either when no negative pressure is applied or when negative pressure is applied. In either situation no external force, caused for example by motion of a patient or an impact is in evidence. By contrast a forced mode of operation occurs when an external force whether compressive, lateral or other is brought to bear upon the wound dressing. Such forces can cause serious damage/prevent healing or a wound.
It is to be noted that in use the dressing may be used “up-side down”, at an angle or vertical. References to upper and lower are thus used for explanation purposes only.
As illustrated in
By providing openings in an upper layer in the transmission layer which have a greater open area than any openings in the lower area build-up of solid particulate matter in the interstitial region between the upper and lower layers of the transmission layer is avoided since any solid or semi-solid matter will flow along the channel and eventually be enabled to pass upwards through the larger openings where the material is taken up by the super-absorber/absorbent material.
The absorbent layer 110 holds liquid collected during the application of negative pressure therapy. By having this layer in fluid communication with, and preferably in contact with, the layer of the transmission layer, the region of the transmission layer 105 is kept at a moist environment. This helps avoid build-up and crusting of the exudate during use.
Whilst certain embodiments of the present invention have so far been described in which the transmission layer is formed as a 3D knit layer, e.g., two layers spaced apart by a monofilament layer, it will be appreciated that certain embodiments of the present invention are not restricted to the use of such a material. In some embodiments, as an alternative to such a 3D knit material one or more layers of a wide variety of materials could be utilized. In each case, according to embodiments of the present invention, the openings presented by layers of the transmission layer are wider and wider as one moves away from the side of the dressing which, in use will be located proximate to the wound. In some embodiments, the transmission layer may be provided by multiple layers of open celled foam. In some embodiments, the foam is reticulated open cell foam. Preferably, the foam is hydrophilic or able to wick aqueous based fluids. The pore size in each layer is selected so that in the foam layer most proximate to the wound side in use the pores have a smallest size. If only one further foam layer is utilized that includes pore sizes which are greater than the pore sizes of the first layer. This helps avoid solid particulate being trapped in the lower layer which thus helps maintain the lower layer in an open configuration in which it is thus able to transmit air throughout the dressing. In certain embodiments, two, three, four or more foam layers may be included. The foam layers may be integrally formed, for example, by selecting a foam having a large pore size and then repeatedly dipping this to a lesser and lesser extent into material which will clog the pores or alternatively, the transmission layer formed by the multiple foam layers may be provided by laminating different types of foam in a layered arrangement or by securing such layers of foam in place in a known manner.
According to certain embodiments of the present invention, the transmission layer is formed by multiple layers of mesh instead of foam or 3D knit materials. For example, fine gauze mesh may be utilized for a wound facing side of the transmission layer and a Hessian mesh having a larger pore size may be located on a distal side of the gauze mesh facing away from the wound in use. The one, two, three or more layers of mesh can be secured together in an appropriate manner, such as being stitched or adhered together or the like. The resultant mat of fibers provides a transmittal layer through which air can be transmitted in the dressing but by selecting the opening sizes in the meshes as one moves through the dressing away from the wound contact side, the accumulation of solid particulate matter in lower layers can be avoided.
After the skin surrounding the wound site 190 is dry, and with reference now to
With reference now to
Turning to
Treatment of the wound site 190 preferably continues until the wound has reached a desired level of healing. In some embodiments, it may be desirable to replace the dressing 100 after a certain time period has elapsed, or if the dressing is full of wound fluids. During such changes, the pump 800 may be kept, with just the dressing 100 being changed.
Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, mean “including but not limited to”, and is they are not intended to (and does not) exclude other moieties, additives, components, integers or steps.
Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
| Number | Date | Country | Kind |
|---|---|---|---|
| 1006983 | Apr 2010 | GB | national |
| 1006985 | Apr 2010 | GB | national |
| 1006986 | Apr 2010 | GB | national |
| 1006988 | Apr 2010 | GB | national |
| 1008347 | May 2010 | GB | national |
This application is a continuation of U.S. patent application Ser. No. 15/633,670, filed on Jun. 26, 2017, which is a continuation of U.S. patent application Ser. No. 14/715,399, filed on May 18, 2015 and issued as U.S. Pat. No. 9,808,561, which is a continuation of U.S. patent application Ser. No. 13/092,042, filed on Apr. 21, 2011 and issued as U.S. Pat. No. 9,061,095, which claims priority to Great Britain Patent Application No. 1006986.2, filed Apr. 27, 2010; Great Britain Patent Application No. 1006983.9, filed Apr. 27, 2010; Great Britain Patent Application No. 1006985.4, filed Apr. 27, 2010; Great Britain Patent Application No. 1006988.8, filed Apr. 27, 2010; and Great Britain Patent Application No. 1008347.5, filed May 19, 2010; all of which are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2280915 | Johnson | Apr 1942 | A |
| 2568933 | Robbins | Sep 1951 | A |
| 2632443 | Lesher | Mar 1953 | A |
| 2682873 | Evans et al. | Jul 1954 | A |
| 2877765 | Bunyan | Mar 1959 | A |
| 2889039 | Schladermundt et al. | Jun 1959 | A |
| 3073304 | Schaar | Jan 1963 | A |
| 3115138 | McElvenny et al. | Dec 1963 | A |
| 3367332 | Groves | Feb 1968 | A |
| 3572340 | Lloyd et al. | Mar 1971 | A |
| 3874387 | Barbieri | Apr 1975 | A |
| 3972328 | Chen | Aug 1976 | A |
| 3993080 | Loseff | Nov 1976 | A |
| 4029598 | Neisius et al. | Jun 1977 | A |
| 4112947 | Nehring | Sep 1978 | A |
| 4117551 | Books et al. | Sep 1978 | A |
| 4136696 | Nehring | Jan 1979 | A |
| 4184510 | Murry et al. | Jan 1980 | A |
| 4217894 | Franetzki | Aug 1980 | A |
| 4219019 | Coates | Aug 1980 | A |
| 4224945 | Cohen | Sep 1980 | A |
| 4294240 | Thill | Oct 1981 | A |
| 4316466 | Babb | Feb 1982 | A |
| 4382441 | Svedman | May 1983 | A |
| 4465485 | Kashmer et al. | Aug 1984 | A |
| 4534356 | Papadakis | Aug 1985 | A |
| 4538920 | Drake et al. | Sep 1985 | A |
| 4541426 | Webster | Sep 1985 | A |
| 4573965 | Russo | Mar 1986 | A |
| 4655754 | Richmond et al. | Apr 1987 | A |
| 4655766 | Theeuwes et al. | Apr 1987 | A |
| 4710165 | McNeil et al. | Dec 1987 | A |
| 4728499 | Fehder | Mar 1988 | A |
| 4753536 | Spehar et al. | Jun 1988 | A |
| 4767026 | Keller | Aug 1988 | A |
| 4771919 | Ernst | Sep 1988 | A |
| 4778446 | Jensen | Oct 1988 | A |
| 4792328 | Beck et al. | Dec 1988 | A |
| 4813942 | Alvarez | Mar 1989 | A |
| 4826494 | Richmond et al. | May 1989 | A |
| 4828546 | McNeil et al. | May 1989 | A |
| 4846164 | Martz | Jul 1989 | A |
| 4872450 | Austad | Oct 1989 | A |
| 4921488 | Maitz et al. | May 1990 | A |
| 4929477 | Will | May 1990 | A |
| 4936834 | Beck et al. | Jun 1990 | A |
| 4969880 | Zamierowski | Nov 1990 | A |
| 4972829 | Knerr | Nov 1990 | A |
| 4994022 | Steffler et al. | Feb 1991 | A |
| 5010115 | Grisoni | Apr 1991 | A |
| 5010883 | Rawlings et al. | Apr 1991 | A |
| 5055198 | Shettigar | Oct 1991 | A |
| 5056510 | Gilman | Oct 1991 | A |
| 5064653 | Sessions et al. | Nov 1991 | A |
| 5073172 | Fell | Dec 1991 | A |
| 5080493 | McKown et al. | Jan 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5115801 | Cartmell et al. | May 1992 | A |
| 5134994 | Say | Aug 1992 | A |
| 5145906 | Chambers et al. | Sep 1992 | A |
| 5152757 | Eriksson | Oct 1992 | A |
| 5160328 | Cartmell et al. | Nov 1992 | A |
| 5167613 | Karami et al. | Dec 1992 | A |
| 5176663 | Svedman et al. | Jan 1993 | A |
| 5181905 | Flam | Jan 1993 | A |
| 5197945 | Cole et al. | Mar 1993 | A |
| 5215519 | Shettigar | Jun 1993 | A |
| 5234419 | Bryant et al. | Aug 1993 | A |
| 5238732 | Krishnan | Aug 1993 | A |
| 5249709 | Duckworth et al. | Oct 1993 | A |
| 5261893 | Zamierowski | Nov 1993 | A |
| 5266326 | Barry et al. | Nov 1993 | A |
| 5266928 | Johnson | Nov 1993 | A |
| 5267952 | Gardner | Dec 1993 | A |
| 5279608 | Cherif Cheikh | Jan 1994 | A |
| 5328614 | Matsumura | Jul 1994 | A |
| 5333760 | Simmen et al. | Aug 1994 | A |
| 5336219 | Krantz | Aug 1994 | A |
| 5354261 | Clark et al. | Oct 1994 | A |
| 5358494 | Svedman | Oct 1994 | A |
| 5364381 | Soga et al. | Nov 1994 | A |
| 5380280 | Peterson | Jan 1995 | A |
| 5380294 | Persson | Jan 1995 | A |
| 5397316 | LaVon et al. | Mar 1995 | A |
| 5437651 | Todd et al. | Aug 1995 | A |
| 5445604 | Lang | Aug 1995 | A |
| 5447492 | Cartmell et al. | Sep 1995 | A |
| 5456660 | Reich et al. | Oct 1995 | A |
| 5456745 | Rorefer et al. | Oct 1995 | A |
| 5480377 | Cartmell et al. | Jan 1996 | A |
| 5489280 | Russell | Feb 1996 | A |
| 5497788 | Inman et al. | Mar 1996 | A |
| 5498338 | Kruger et al. | Mar 1996 | A |
| 5527293 | Zamierowski | Jun 1996 | A |
| 5538500 | Peterson | Jul 1996 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5553998 | Muhlhoff et al. | Sep 1996 | A |
| 5562107 | Lavender et al. | Oct 1996 | A |
| 5579765 | Cox et al. | Dec 1996 | A |
| 5582596 | Fukunaga et al. | Dec 1996 | A |
| 5583114 | Barrows et al. | Dec 1996 | A |
| 5603946 | Constantine | Feb 1997 | A |
| 5609271 | Keller et al. | Mar 1997 | A |
| 5612050 | Rowe et al. | Mar 1997 | A |
| 5624423 | Anjur et al. | Apr 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5637080 | Geng | Jun 1997 | A |
| 5643189 | Masini | Jul 1997 | A |
| 5645081 | Argenta et al. | Jul 1997 | A |
| 5660823 | Chakrabarti et al. | Aug 1997 | A |
| 5662599 | Reich et al. | Sep 1997 | A |
| 5702356 | Hathman | Dec 1997 | A |
| 5704905 | Jensen et al. | Jan 1998 | A |
| 5707499 | Joshi et al. | Jan 1998 | A |
| 5713384 | Roach et al. | Feb 1998 | A |
| 5717030 | Dunn et al. | Feb 1998 | A |
| 5747064 | Burnett et al. | May 1998 | A |
| 5759570 | Arnold | Jun 1998 | A |
| 5776193 | Kwan et al. | Jul 1998 | A |
| 5785688 | Joshi et al. | Jul 1998 | A |
| 5795439 | Euripides et al. | Aug 1998 | A |
| 5804021 | Abuto et al. | Sep 1998 | A |
| 5827213 | Jensen | Oct 1998 | A |
| 5833646 | Masini | Nov 1998 | A |
| 5834007 | Kubota | Nov 1998 | A |
| 5840052 | Johns | Nov 1998 | A |
| 5843011 | Lucas | Dec 1998 | A |
| 5843025 | Shaari | Dec 1998 | A |
| 5852126 | Barnard et al. | Dec 1998 | A |
| 5868724 | Dierckes, Jr. et al. | Feb 1999 | A |
| 5868933 | Patrick et al. | Feb 1999 | A |
| 5874500 | Rhee et al. | Feb 1999 | A |
| 5876611 | Shettigar | Mar 1999 | A |
| 5897541 | Uitenbrock et al. | Apr 1999 | A |
| 5945115 | Dunn et al. | Aug 1999 | A |
| 5962010 | Greff et al. | Oct 1999 | A |
| 5964723 | Augustine | Oct 1999 | A |
| 5981822 | Addison | Nov 1999 | A |
| 5998472 | Berger et al. | Dec 1999 | A |
| 6040493 | Cooke et al. | Mar 2000 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6075177 | Bahia et al. | Jun 2000 | A |
| 6103951 | Freeman | Aug 2000 | A |
| 6124520 | Roberts | Sep 2000 | A |
| 6124521 | Roberts | Sep 2000 | A |
| 6135116 | Vogel et al. | Oct 2000 | A |
| 6142982 | Hunt et al. | Nov 2000 | A |
| 6143352 | Clark et al. | Nov 2000 | A |
| 6165201 | Sawhney et al. | Dec 2000 | A |
| 6167613 | Karami | Jan 2001 | B1 |
| 6168788 | Wortham | Jan 2001 | B1 |
| 6168800 | Dobos et al. | Jan 2001 | B1 |
| 6203654 | McFall et al. | Mar 2001 | B1 |
| 6207875 | Lindqvist et al. | Mar 2001 | B1 |
| 6214332 | Askill et al. | Apr 2001 | B1 |
| 6225523 | Masini | May 2001 | B1 |
| 6252129 | Coffee | Jun 2001 | B1 |
| 6254567 | Treu et al. | Jul 2001 | B1 |
| 6255552 | Cummings et al. | Jul 2001 | B1 |
| 6287521 | Quay et al. | Sep 2001 | B1 |
| 6291050 | Cree et al. | Sep 2001 | B1 |
| 6297422 | Hansen et al. | Oct 2001 | B1 |
| 6297423 | Schoenfeldt et al. | Oct 2001 | B1 |
| 6345623 | Heaton et al. | Feb 2002 | B1 |
| 6362390 | Carlucci et al. | Mar 2002 | B1 |
| 6391294 | Dettmar et al. | May 2002 | B1 |
| 6398761 | Bills et al. | Jun 2002 | B1 |
| 6398767 | Fleischmann | Jun 2002 | B1 |
| 6440167 | Shimizu | Aug 2002 | B2 |
| 6447802 | Sessions et al. | Sep 2002 | B2 |
| 6450773 | Upton | Sep 2002 | B1 |
| 6458109 | Henley et al. | Oct 2002 | B1 |
| 6465708 | Augustine | Oct 2002 | B1 |
| 6468295 | Augustine et al. | Oct 2002 | B2 |
| 6471982 | Lydon et al. | Oct 2002 | B1 |
| 6486285 | Fujita | Nov 2002 | B2 |
| 6491684 | Joshi et al. | Dec 2002 | B1 |
| 6495127 | Wallace et al. | Dec 2002 | B1 |
| 6506175 | Goldstein | Jan 2003 | B1 |
| 6509031 | Miller et al. | Jan 2003 | B1 |
| 6521251 | Askill et al. | Feb 2003 | B2 |
| 6528696 | Ireland | Mar 2003 | B1 |
| 6547467 | Quintero | Apr 2003 | B2 |
| 6553998 | Heaton et al. | Apr 2003 | B2 |
| 6566575 | Stickels et al. | May 2003 | B1 |
| 6575940 | Levinson et al. | Jun 2003 | B1 |
| 6586653 | Graeme, III et al. | Jul 2003 | B2 |
| 6596704 | Court et al. | Jul 2003 | B1 |
| 6599262 | Masini | Jul 2003 | B1 |
| 6613953 | Altura | Sep 2003 | B1 |
| 6626891 | Ohmstede | Sep 2003 | B2 |
| 6627216 | Brandt et al. | Sep 2003 | B2 |
| 6629774 | Guruendeman | Oct 2003 | B1 |
| 6648862 | Watson | Nov 2003 | B2 |
| 6673028 | Argenta et al. | Jan 2004 | B1 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6695823 | Lina et al. | Feb 2004 | B1 |
| 6695824 | Howard et al. | Feb 2004 | B2 |
| 6706940 | Worthley | Mar 2004 | B2 |
| 6719742 | McCormack et al. | Apr 2004 | B1 |
| 6730299 | Tayot et al. | May 2004 | B1 |
| 6752794 | Lockwood et al. | Jun 2004 | B2 |
| 6755807 | Risk et al. | Jun 2004 | B2 |
| 6762337 | Boukanov et al. | Jul 2004 | B2 |
| 6764459 | Donaldson | Jul 2004 | B1 |
| 6764462 | Risk, Jr. et al. | Jul 2004 | B2 |
| 6767334 | Randolph | Jul 2004 | B1 |
| 6775807 | Lowther et al. | Aug 2004 | B2 |
| 6776769 | Smith | Aug 2004 | B2 |
| 6787682 | Gilman | Sep 2004 | B2 |
| 6790438 | Constancis et al. | Sep 2004 | B1 |
| 6814079 | Heaton et al. | Nov 2004 | B2 |
| 6824533 | Risk, Jr. et al. | Nov 2004 | B2 |
| 6838589 | Liedtke et al. | Jan 2005 | B2 |
| 6855135 | Lockwood et al. | Feb 2005 | B2 |
| 6856821 | Johnson | Feb 2005 | B2 |
| 6936037 | Bubb et al. | Aug 2005 | B2 |
| 6951553 | Bubb et al. | Oct 2005 | B2 |
| 6960179 | Gura | Nov 2005 | B2 |
| 6977323 | Swenson | Dec 2005 | B1 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 6994702 | Johnson | Feb 2006 | B1 |
| 6998511 | Worthley | Feb 2006 | B2 |
| 7004915 | Boynton et al. | Feb 2006 | B2 |
| 7022113 | Lockwood et al. | Apr 2006 | B2 |
| 7049478 | Smith et al. | May 2006 | B1 |
| 7067709 | Murata et al. | Jun 2006 | B2 |
| 7070584 | Johnson et al. | Jul 2006 | B2 |
| 7077832 | Fleischmann | Jul 2006 | B2 |
| 7108683 | Zamierowski | Sep 2006 | B2 |
| 7117869 | Heaton et al. | Oct 2006 | B2 |
| 7118545 | Boyde | Oct 2006 | B2 |
| 7128735 | Weston | Oct 2006 | B2 |
| 7129210 | Lowinger et al. | Oct 2006 | B2 |
| 7195624 | Lockwood | Mar 2007 | B2 |
| 7214202 | Vogel et al. | May 2007 | B1 |
| 7216651 | Argenta et al. | May 2007 | B2 |
| 7238850 | Shimanuki | Jul 2007 | B2 |
| 7294751 | Propp et al. | Nov 2007 | B2 |
| 7294752 | Propp | Nov 2007 | B1 |
| 7303757 | Schankereli et al. | Dec 2007 | B2 |
| 7335809 | Riesinger | Feb 2008 | B2 |
| 7338482 | Lockwood et al. | Mar 2008 | B2 |
| 7361184 | Joshi | Apr 2008 | B2 |
| 7381211 | Zamierowski | Jun 2008 | B2 |
| 7381859 | Hunt et al. | Jun 2008 | B2 |
| 7401394 | Muller | Jul 2008 | B1 |
| 7429689 | Chen et al. | Sep 2008 | B2 |
| 7438705 | Karpowicz et al. | Oct 2008 | B2 |
| 7468471 | Sigurjonsson et al. | Dec 2008 | B2 |
| 7470830 | Sigurjonsson et al. | Dec 2008 | B2 |
| 7476205 | Erdmann | Jan 2009 | B2 |
| 7485112 | Karpowicz et al. | Feb 2009 | B2 |
| 7494482 | Orgill et al. | Feb 2009 | B2 |
| 7503910 | Adahan | Mar 2009 | B2 |
| 7507870 | Nielsen et al. | Mar 2009 | B2 |
| 7511187 | Kelly | Mar 2009 | B2 |
| 7524286 | Johnson | Apr 2009 | B2 |
| 7524315 | Blott et al. | Apr 2009 | B2 |
| 7534240 | Johnson | May 2009 | B1 |
| 7534927 | Lockwood | May 2009 | B2 |
| 7563940 | Kurata | Jul 2009 | B2 |
| 7569742 | Haggstrom et al. | Aug 2009 | B2 |
| 7576256 | Björnberg et al. | Aug 2009 | B2 |
| 7601129 | Aali | Oct 2009 | B2 |
| 7605298 | Bechert et al. | Oct 2009 | B2 |
| 7612247 | Oyaski | Nov 2009 | B2 |
| 7615036 | Joshi et al. | Nov 2009 | B2 |
| 7622629 | Aail | Nov 2009 | B2 |
| 7625362 | Boehringer et al. | Dec 2009 | B2 |
| 7645269 | Zamierowski | Jan 2010 | B2 |
| 7676400 | Dillon | Mar 2010 | B1 |
| 7699823 | Haggstrom et al. | Apr 2010 | B2 |
| 7699830 | Martin | Apr 2010 | B2 |
| 7700819 | Ambrosio et al. | Apr 2010 | B2 |
| 7708724 | Weston | May 2010 | B2 |
| 7717313 | Criscuolo et al. | May 2010 | B2 |
| 7718249 | Russell et al. | May 2010 | B2 |
| 7722582 | Lina et al. | May 2010 | B2 |
| 7723560 | Lockwood et al. | May 2010 | B2 |
| 7723561 | Propp | May 2010 | B2 |
| 7731702 | Bybordi et al. | Jun 2010 | B2 |
| 7745681 | Ferguson | Jun 2010 | B1 |
| 7749531 | Booher | Jul 2010 | B2 |
| 7753894 | Blott et al. | Jul 2010 | B2 |
| 7759537 | Bishop et al. | Jul 2010 | B2 |
| 7759538 | Fleischmann | Jul 2010 | B2 |
| 7759539 | Shaw et al. | Jul 2010 | B2 |
| 7775998 | Riesinger | Aug 2010 | B2 |
| 7776028 | Miller et al. | Aug 2010 | B2 |
| 7779625 | Joshi et al. | Aug 2010 | B2 |
| 7790945 | Watson, Jr. | Sep 2010 | B1 |
| 7794438 | Henley et al. | Sep 2010 | B2 |
| 7794450 | Blott et al. | Sep 2010 | B2 |
| 7803980 | Griffiths et al. | Sep 2010 | B2 |
| 7811269 | Boynton et al. | Oct 2010 | B2 |
| 7815616 | Boehringer et al. | Oct 2010 | B2 |
| 7816577 | Aali | Oct 2010 | B2 |
| 7828782 | Suzuki | Nov 2010 | B2 |
| 7838716 | de Luis et al. | Nov 2010 | B2 |
| 7838717 | Haggstrom et al. | Nov 2010 | B2 |
| 7846141 | Weston | Dec 2010 | B2 |
| 7857806 | Karpowicz et al. | Dec 2010 | B2 |
| 7858838 | Holm et al. | Dec 2010 | B2 |
| 7862831 | Wang et al. | Jan 2011 | B2 |
| 7880050 | Robinson et al. | Feb 2011 | B2 |
| 7884258 | Boehringer et al. | Feb 2011 | B2 |
| 7896823 | Mangrum et al. | Mar 2011 | B2 |
| 7896856 | Petrosenko et al. | Mar 2011 | B2 |
| 7909805 | Weston | Mar 2011 | B2 |
| 7910135 | St. John et al. | Mar 2011 | B2 |
| 7910791 | Coffey | Mar 2011 | B2 |
| 7922703 | Riesinger | Apr 2011 | B2 |
| 7927318 | Risk, Jr. et al. | Apr 2011 | B2 |
| 7931630 | Nishtala et al. | Apr 2011 | B2 |
| 7935066 | Shives et al. | May 2011 | B2 |
| 7959624 | Riesinger | Jun 2011 | B2 |
| 7964766 | Blott et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7982087 | Greener et al. | Jul 2011 | B2 |
| D642594 | Mattson et al. | Aug 2011 | S |
| 7988673 | Wright et al. | Aug 2011 | B2 |
| 7998125 | Weston | Aug 2011 | B2 |
| 8007164 | Miyano et al. | Aug 2011 | B2 |
| 8007257 | Heaton et al. | Aug 2011 | B2 |
| 8021347 | Vitaris et al. | Sep 2011 | B2 |
| 8025650 | Anderson et al. | Sep 2011 | B2 |
| 8034037 | Adams et al. | Oct 2011 | B2 |
| 8062272 | Weston | Nov 2011 | B2 |
| 8062331 | Zamierowski | Nov 2011 | B2 |
| 8080702 | Blott et al. | Dec 2011 | B2 |
| 8084663 | Watson, Jr. | Dec 2011 | B2 |
| 8092436 | Christensen | Jan 2012 | B2 |
| 8097272 | Addison | Jan 2012 | B2 |
| 8100887 | Weston et al. | Jan 2012 | B2 |
| 8105295 | Blott et al. | Jan 2012 | B2 |
| 8118794 | Weston et al. | Feb 2012 | B2 |
| 8119160 | Looney et al. | Feb 2012 | B2 |
| 8133211 | Cavanaugh, II et al. | Mar 2012 | B2 |
| 8147468 | Barta et al. | Apr 2012 | B2 |
| 8152785 | Vitaris | Apr 2012 | B2 |
| 8158844 | McNeil | Apr 2012 | B2 |
| 8162907 | Heagle | Apr 2012 | B2 |
| 8162909 | Blott et al. | Apr 2012 | B2 |
| 8168848 | Lockwood et al. | May 2012 | B2 |
| 8188331 | Barta et al. | May 2012 | B2 |
| 8202261 | Kazala, Jr. et al. | Jun 2012 | B2 |
| 8207392 | Haggstrom et al. | Jun 2012 | B2 |
| 8211071 | Mormino et al. | Jul 2012 | B2 |
| 8212101 | Propp | Jul 2012 | B2 |
| 8215929 | Shen et al. | Jul 2012 | B2 |
| 8226942 | Charier et al. | Jul 2012 | B2 |
| 8235955 | Blott et al. | Aug 2012 | B2 |
| 8235972 | Adahan | Aug 2012 | B2 |
| 8241261 | Randolph et al. | Aug 2012 | B2 |
| 8246607 | Karpowicz et al. | Aug 2012 | B2 |
| 8251979 | Malhi | Aug 2012 | B2 |
| 8252971 | Aali et al. | Aug 2012 | B2 |
| 8257327 | Blott et al. | Sep 2012 | B2 |
| 8257328 | Augustine et al. | Sep 2012 | B2 |
| 8267908 | Coulthard | Sep 2012 | B2 |
| 8273368 | Ambrosio et al. | Sep 2012 | B2 |
| 8282611 | Weston | Oct 2012 | B2 |
| 8294586 | Pidgeon et al. | Oct 2012 | B2 |
| 8303552 | Weston | Nov 2012 | B2 |
| 8308714 | Weston et al. | Nov 2012 | B2 |
| 8314283 | Kingsford et al. | Nov 2012 | B2 |
| 8317774 | Adahan | Nov 2012 | B2 |
| 8323264 | Weston et al. | Dec 2012 | B2 |
| 8328858 | Barsky et al. | Dec 2012 | B2 |
| 8348910 | Blott et al. | Jan 2013 | B2 |
| 8372049 | Jaeb et al. | Feb 2013 | B2 |
| 8372050 | Jaeb et al. | Feb 2013 | B2 |
| 8376972 | Fleischmann | Feb 2013 | B2 |
| 8382731 | Johannison | Feb 2013 | B2 |
| 8403899 | Sherman | Mar 2013 | B2 |
| 8404921 | Lee et al. | Mar 2013 | B2 |
| D679819 | Peron | Apr 2013 | S |
| D679820 | Peron | Apr 2013 | S |
| 8409159 | Hu et al. | Apr 2013 | B2 |
| 8410189 | Carnahan et al. | Apr 2013 | B2 |
| 8425478 | Olson | Apr 2013 | B2 |
| 8444612 | Patel et al. | May 2013 | B2 |
| 8449509 | Weston | May 2013 | B2 |
| 8460255 | Joshi et al. | Jun 2013 | B2 |
| 8494349 | Gordon | Jul 2013 | B2 |
| 8506554 | Adahan | Aug 2013 | B2 |
| 8535283 | Heaton et al. | Sep 2013 | B2 |
| 8535296 | Blott et al. | Sep 2013 | B2 |
| 8540687 | Henley et al. | Sep 2013 | B2 |
| 8545466 | Andresen et al. | Oct 2013 | B2 |
| 8556871 | Mormino et al. | Oct 2013 | B2 |
| 8568386 | Malhi | Oct 2013 | B2 |
| 8569566 | Blott et al. | Oct 2013 | B2 |
| 8624077 | Rosenberg | Jan 2014 | B2 |
| 8628505 | Weston | Jan 2014 | B2 |
| 8641691 | Fink | Feb 2014 | B2 |
| 8663198 | Buan et al. | Mar 2014 | B2 |
| 8679079 | Heaton et al. | Mar 2014 | B2 |
| 8680360 | Greener et al. | Mar 2014 | B2 |
| 8715256 | Greener | May 2014 | B2 |
| 8734410 | Hall et al. | May 2014 | B2 |
| 8753670 | Delmotte | Jun 2014 | B2 |
| 8764732 | Hartwell | Jul 2014 | B2 |
| 8784392 | Vess et al. | Jul 2014 | B2 |
| 8791316 | Greener | Jul 2014 | B2 |
| 8795243 | Weston | Aug 2014 | B2 |
| 8795244 | Randolph et al. | Aug 2014 | B2 |
| 8795247 | Bennett et al. | Aug 2014 | B2 |
| 8795635 | Tamarkin et al. | Aug 2014 | B2 |
| 8795713 | Makower et al. | Aug 2014 | B2 |
| 8795800 | Evans | Aug 2014 | B2 |
| 8801685 | Armstrong et al. | Aug 2014 | B2 |
| 8808274 | Hartwell | Aug 2014 | B2 |
| 8814842 | Coulthard et al. | Aug 2014 | B2 |
| 8829263 | Haggstrom et al. | Sep 2014 | B2 |
| 8834451 | Blott et al. | Sep 2014 | B2 |
| 8834452 | Hudspeth et al. | Sep 2014 | B2 |
| 8843327 | Vernon-Harcourt et al. | Sep 2014 | B2 |
| 8864748 | Coulthard et al. | Oct 2014 | B2 |
| 8915895 | Jaeb et al. | Dec 2014 | B2 |
| 8916742 | Smith | Dec 2014 | B2 |
| 8956336 | Haggstrom et al. | Feb 2015 | B2 |
| 8968773 | Thomas et al. | Mar 2015 | B2 |
| 9012714 | Fleischmann | Apr 2015 | B2 |
| 9028872 | Gaserod et al. | May 2015 | B2 |
| 9033942 | Vess | May 2015 | B2 |
| 9044579 | Blott et al. | Jun 2015 | B2 |
| 9061095 | Adie et al. | Jun 2015 | B2 |
| 9168330 | Joshi et al. | Oct 2015 | B2 |
| 9180231 | Greener | Nov 2015 | B2 |
| 9198801 | Weston | Dec 2015 | B2 |
| 9199012 | Vitaris et al. | Dec 2015 | B2 |
| 9220822 | Hartwell et al. | Dec 2015 | B2 |
| 9302033 | Riesinger | Apr 2016 | B2 |
| 9375353 | Vitaris et al. | Jun 2016 | B2 |
| 9375521 | Hudspeth et al. | Jun 2016 | B2 |
| 9381283 | Adams et al. | Jul 2016 | B2 |
| 9421309 | Robinson et al. | Aug 2016 | B2 |
| 9446178 | Blott et al. | Sep 2016 | B2 |
| 9452248 | Blott et al. | Sep 2016 | B2 |
| 9629986 | Patel et al. | Apr 2017 | B2 |
| 9820888 | Greener et al. | Nov 2017 | B2 |
| 10080689 | Hall et al. | Sep 2018 | B2 |
| 20010004082 | Keller et al. | Jun 2001 | A1 |
| 20010034499 | Sessions et al. | Oct 2001 | A1 |
| 20010043913 | Spaans et al. | Nov 2001 | A1 |
| 20010043943 | Coffey | Nov 2001 | A1 |
| 20010051178 | Blatchford et al. | Dec 2001 | A1 |
| 20020002209 | Mork | Jan 2002 | A1 |
| 20020019602 | Geng | Feb 2002 | A1 |
| 20020038826 | Hurray et al. | Apr 2002 | A1 |
| 20020052570 | Naimer | May 2002 | A1 |
| 20020110672 | Muratore-Pallatino et al. | Aug 2002 | A1 |
| 20020122771 | Holland et al. | Sep 2002 | A1 |
| 20020143286 | Tumey | Oct 2002 | A1 |
| 20020145007 | Sawhney et al. | Oct 2002 | A1 |
| 20020169405 | Roberts | Nov 2002 | A1 |
| 20020183702 | Henley et al. | Dec 2002 | A1 |
| 20020187182 | Kramer et al. | Dec 2002 | A1 |
| 20020198490 | Wirt et al. | Dec 2002 | A1 |
| 20030009122 | Veras | Jan 2003 | A1 |
| 20030014022 | Lockwood | Jan 2003 | A1 |
| 20030021775 | Freeman | Jan 2003 | A1 |
| 20030040478 | Drucker et al. | Feb 2003 | A1 |
| 20030045825 | Etheredge, III | Mar 2003 | A1 |
| 20030050590 | Kirsch | Mar 2003 | A1 |
| 20030069535 | Shalaby | Apr 2003 | A1 |
| 20030069563 | Johnson | Apr 2003 | A1 |
| 20030114818 | Benecke et al. | Jun 2003 | A1 |
| 20030125646 | Whitlock | Jul 2003 | A1 |
| 20030125649 | Mcintosh et al. | Jul 2003 | A1 |
| 20030143189 | Askill et al. | Jul 2003 | A1 |
| 20030144619 | Augustine | Jul 2003 | A1 |
| 20030171675 | Rosenberg | Sep 2003 | A1 |
| 20030175798 | Raees et al. | Sep 2003 | A1 |
| 20030180341 | Gooch et al. | Sep 2003 | A1 |
| 20030183653 | Bills | Oct 2003 | A1 |
| 20030199800 | Levin | Oct 2003 | A1 |
| 20030203011 | Abuelyaman et al. | Oct 2003 | A1 |
| 20030212357 | Pace | Nov 2003 | A1 |
| 20030212359 | Butler | Nov 2003 | A1 |
| 20030212431 | Brady et al. | Nov 2003 | A1 |
| 20030219469 | Johnson et al. | Nov 2003 | A1 |
| 20030225347 | Argenta et al. | Dec 2003 | A1 |
| 20040019337 | Moberg-Alehammar et al. | Jan 2004 | A1 |
| 20040019342 | Nagasuna et al. | Jan 2004 | A1 |
| 20040033466 | Shellard et al. | Feb 2004 | A1 |
| 20040037897 | Benjamin et al. | Feb 2004 | A1 |
| 20040039391 | Argenta et al. | Feb 2004 | A1 |
| 20040049187 | Burnett et al. | Mar 2004 | A1 |
| 20040054338 | Bybordi et al. | Mar 2004 | A1 |
| 20040057855 | Gerlach et al. | Mar 2004 | A1 |
| 20040064111 | Lockwood et al. | Apr 2004 | A1 |
| 20040073152 | Karason et al. | Apr 2004 | A1 |
| 20040078011 | Stevens | Apr 2004 | A1 |
| 20040106888 | Lutri et al. | Jun 2004 | A1 |
| 20040122434 | Argenta et al. | Jun 2004 | A1 |
| 20040127863 | Bubb et al. | Jul 2004 | A1 |
| 20040138602 | Rossen | Jul 2004 | A1 |
| 20040167617 | Voellmicke et al. | Aug 2004 | A1 |
| 20040171998 | Marasco, Jr. | Sep 2004 | A1 |
| 20040193218 | Butler | Sep 2004 | A1 |
| 20040241214 | Kirkwood et al. | Dec 2004 | A1 |
| 20040243042 | Lipman | Dec 2004 | A1 |
| 20050015036 | Lutri et al. | Jan 2005 | A1 |
| 20050020955 | Sanders et al. | Jan 2005 | A1 |
| 20050131327 | Lockwood et al. | Jun 2005 | A1 |
| 20050230422 | Muller et al. | Oct 2005 | A1 |
| 20060009744 | Edrman et al. | Jan 2006 | A1 |
| 20060020234 | Chou et al. | Jan 2006 | A1 |
| 20060029650 | Coffey | Feb 2006 | A1 |
| 20060070458 | Jones et al. | Apr 2006 | A1 |
| 20060079599 | Arthur | Apr 2006 | A1 |
| 20060100586 | Karpowicz | May 2006 | A1 |
| 20060100597 | Miskie | May 2006 | A1 |
| 20060122548 | Abrams | Jun 2006 | A1 |
| 20060161123 | Kudo et al. | Jul 2006 | A1 |
| 20060173514 | Biel et al. | Aug 2006 | A1 |
| 20060206047 | Lampe et al. | Sep 2006 | A1 |
| 20060253082 | Mcintosh et al. | Nov 2006 | A1 |
| 20060273109 | Keller | Dec 2006 | A1 |
| 20070003604 | Jones | Jan 2007 | A1 |
| 20070004896 | Ito et al. | Jan 2007 | A1 |
| 20070009580 | DiCosmo et al. | Jan 2007 | A1 |
| 20070027414 | Hoffman et al. | Feb 2007 | A1 |
| 20070032762 | Vogel | Feb 2007 | A1 |
| 20070032763 | Vogel | Feb 2007 | A1 |
| 20070038172 | Zamierowski | Feb 2007 | A1 |
| 20070040454 | Freudenberger et al. | Feb 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070078467 | Mullen | Apr 2007 | A1 |
| 20070100308 | Miyairi | May 2007 | A1 |
| 20070141101 | Nugent et al. | Jun 2007 | A1 |
| 20070147947 | Stenton et al. | Jun 2007 | A1 |
| 20070164047 | Reidt et al. | Jul 2007 | A1 |
| 20070185463 | Mulligan | Aug 2007 | A1 |
| 20070203062 | Ellis-Behnke et al. | Aug 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070239232 | Kurtz et al. | Oct 2007 | A1 |
| 20070260207 | Ugander et al. | Nov 2007 | A1 |
| 20070282236 | LaGreca | Dec 2007 | A1 |
| 20080004549 | Anderson et al. | Jan 2008 | A1 |
| 20080031748 | Ihle et al. | Feb 2008 | A1 |
| 20080058691 | Sorensen | Mar 2008 | A1 |
| 20080060550 | MacDonald et al. | Mar 2008 | A1 |
| 20080089173 | Lu et al. | Apr 2008 | A1 |
| 20080132821 | Propp et al. | Jun 2008 | A1 |
| 20080167592 | Greer | Jul 2008 | A1 |
| 20080200905 | Heaton | Aug 2008 | A1 |
| 20080206155 | Tamarkin et al. | Aug 2008 | A1 |
| 20080208147 | Argenta et al. | Aug 2008 | A1 |
| 20080208163 | Wilkie | Aug 2008 | A1 |
| 20080223378 | Henderson et al. | Sep 2008 | A1 |
| 20080254103 | Harris et al. | Oct 2008 | A1 |
| 20080287880 | Keller | Nov 2008 | A1 |
| 20080294147 | Radl et al. | Nov 2008 | A1 |
| 20080300555 | Olson et al. | Dec 2008 | A1 |
| 20080306407 | Taylor | Dec 2008 | A1 |
| 20080306456 | Riesinger | Dec 2008 | A1 |
| 20080312572 | Riesinger | Dec 2008 | A1 |
| 20080314929 | Keller | Dec 2008 | A1 |
| 20090005746 | Nielsen et al. | Jan 2009 | A1 |
| 20090020561 | Keller | Jan 2009 | A1 |
| 20090022779 | Kelly et al. | Jan 2009 | A1 |
| 20090030086 | Eady et al. | Jan 2009 | A1 |
| 20090036873 | Nielsen et al. | Feb 2009 | A1 |
| 20090054855 | Blott et al. | Feb 2009 | A1 |
| 20090082740 | Lockwood et al. | Mar 2009 | A1 |
| 20090093550 | Rolfes et al. | Apr 2009 | A1 |
| 20090098073 | MacDonald et al. | Apr 2009 | A1 |
| 20090125004 | Shen et al. | May 2009 | A1 |
| 20090131892 | Karpowicz et al. | May 2009 | A1 |
| 20090134186 | Keller | May 2009 | A1 |
| 20090137973 | Karpowicz et al. | May 2009 | A1 |
| 20090157017 | Ambrosio | Jun 2009 | A1 |
| 20090157024 | Song | Jun 2009 | A1 |
| 20090196844 | Choi et al. | Aug 2009 | A1 |
| 20090198201 | Adahan | Aug 2009 | A1 |
| 20090204085 | Biggie et al. | Aug 2009 | A1 |
| 20090216170 | Robinson et al. | Aug 2009 | A1 |
| 20090221977 | Blott et al. | Sep 2009 | A1 |
| 20090221990 | Jaeb et al. | Sep 2009 | A1 |
| 20090227935 | Zanella et al. | Sep 2009 | A1 |
| 20090234306 | Vitaris | Sep 2009 | A1 |
| 20090254053 | Svensby et al. | Oct 2009 | A1 |
| 20090270820 | Johnson | Oct 2009 | A1 |
| 20090275872 | Addison et al. | Nov 2009 | A1 |
| 20090275922 | Coulthard et al. | Nov 2009 | A1 |
| 20090293887 | Wilkes et al. | Dec 2009 | A1 |
| 20090299249 | Wilkes et al. | Dec 2009 | A1 |
| 20090299251 | Buan | Dec 2009 | A1 |
| 20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
| 20090299257 | Long et al. | Dec 2009 | A1 |
| 20090299306 | Buan | Dec 2009 | A1 |
| 20090299308 | Kazala et al. | Dec 2009 | A1 |
| 20090299340 | Kazala et al. | Dec 2009 | A1 |
| 20090312723 | Blott et al. | Dec 2009 | A1 |
| 20100004611 | Aali | Jan 2010 | A1 |
| 20100010462 | Kurata | Jan 2010 | A1 |
| 20100016767 | Jones et al. | Jan 2010 | A1 |
| 20100022972 | Lina et al. | Jan 2010 | A1 |
| 20100030170 | Keller et al. | Feb 2010 | A1 |
| 20100030171 | Canada et al. | Feb 2010 | A1 |
| 20100030178 | MacMeccan et al. | Feb 2010 | A1 |
| 20100036305 | Green | Feb 2010 | A1 |
| 20100036334 | Heagle et al. | Feb 2010 | A1 |
| 20100055158 | Vitaris et al. | Mar 2010 | A1 |
| 20100069858 | Olson | Mar 2010 | A1 |
| 20100069863 | Olson | Mar 2010 | A1 |
| 20100084074 | McClernon et al. | Apr 2010 | A1 |
| 20100106112 | Vogel | Apr 2010 | A1 |
| 20100106120 | Holm | Apr 2010 | A1 |
| 20100106121 | Holm | Apr 2010 | A1 |
| 20100121286 | Locke et al. | May 2010 | A1 |
| 20100122417 | Vrzalik et al. | May 2010 | A1 |
| 20100125234 | Smith | May 2010 | A1 |
| 20100125258 | Coulthard et al. | May 2010 | A1 |
| 20100150991 | Bernstein | Jun 2010 | A1 |
| 20100159192 | Cotton | Jun 2010 | A1 |
| 20100191196 | Heagle | Jul 2010 | A1 |
| 20100191198 | Heagle | Jul 2010 | A1 |
| 20100196106 | Allen | Aug 2010 | A1 |
| 20100210986 | Sanders | Aug 2010 | A1 |
| 20100217177 | Cali et al. | Aug 2010 | A1 |
| 20100230467 | Crisuolo et al. | Sep 2010 | A1 |
| 20100249733 | Blott et al. | Sep 2010 | A9 |
| 20100259406 | Caso et al. | Oct 2010 | A1 |
| 20100262090 | Riesinger | Oct 2010 | A1 |
| 20100262091 | Larsson | Oct 2010 | A1 |
| 20100280468 | Haggstrom et al. | Nov 2010 | A1 |
| 20100305490 | Coulthard et al. | Dec 2010 | A1 |
| 20100318043 | Malhi et al. | Dec 2010 | A1 |
| 20100318052 | Ha et al. | Dec 2010 | A1 |
| 20110004172 | Eckstein et al. | Jan 2011 | A1 |
| 20110015593 | Svedman et al. | Jan 2011 | A1 |
| 20110021431 | Jones et al. | Jan 2011 | A1 |
| 20110021964 | Larsen et al. | Jan 2011 | A1 |
| 20110028919 | Johnnison et al. | Feb 2011 | A1 |
| 20110028921 | Hartwell et al. | Feb 2011 | A1 |
| 20110033503 | Sinko et al. | Feb 2011 | A1 |
| 20110034888 | Aali | Feb 2011 | A1 |
| 20110034892 | Buan | Feb 2011 | A1 |
| 20110052664 | Tennican et al. | Mar 2011 | A1 |
| 20110054421 | Hartwell | Mar 2011 | A1 |
| 20110054422 | Locke et al. | Mar 2011 | A1 |
| 20110054423 | Blott et al. | Mar 2011 | A1 |
| 20110086077 | McCrea et al. | Apr 2011 | A1 |
| 20110092927 | Wilkes et al. | Apr 2011 | A1 |
| 20110092958 | Jacobs | Apr 2011 | A1 |
| 20110098621 | Fabo et al. | Apr 2011 | A1 |
| 20110105963 | Hu et al. | May 2011 | A1 |
| 20110106030 | Scholz | May 2011 | A1 |
| 20110112492 | Bharti et al. | May 2011 | A1 |
| 20110118683 | Weston | May 2011 | A1 |
| 20110125066 | Robinson et al. | May 2011 | A1 |
| 20110130712 | Topaz | Jun 2011 | A1 |
| 20110137222 | Masini | Jun 2011 | A1 |
| 20110172617 | Riesinger | Jul 2011 | A1 |
| 20110178375 | Forster | Jul 2011 | A1 |
| 20110218509 | Dontas | Sep 2011 | A1 |
| 20110224631 | Simmons | Sep 2011 | A1 |
| 20110245682 | Robinson et al. | Oct 2011 | A1 |
| 20110245788 | Marquez Canada | Oct 2011 | A1 |
| 20110247636 | Pollack | Oct 2011 | A1 |
| 20110257572 | Locke et al. | Oct 2011 | A1 |
| 20110295220 | Heaton et al. | Dec 2011 | A1 |
| 20120041402 | Greener | Feb 2012 | A1 |
| 20120051945 | Orndorff et al. | Mar 2012 | A1 |
| 20120065664 | Avitable et al. | Mar 2012 | A1 |
| 20120095380 | Gergley et al. | Apr 2012 | A1 |
| 20120095426 | Visscher et al. | Apr 2012 | A1 |
| 20120101465 | Mcguire, Jr. | Apr 2012 | A1 |
| 20120123311 | Weidemann-Hendrickson et al. | May 2012 | A1 |
| 20120123358 | Hall et al. | May 2012 | A1 |
| 20120172778 | Rastegar et al. | Jul 2012 | A1 |
| 20120203145 | Nilsson | Aug 2012 | A1 |
| 20120203189 | Barta et al. | Aug 2012 | A1 |
| 20120222687 | Czajka, Jr. et al. | Sep 2012 | A1 |
| 20120232502 | Lowing | Sep 2012 | A1 |
| 20120238932 | Atteia et al. | Sep 2012 | A1 |
| 20130090615 | Jaeb et al. | Apr 2013 | A1 |
| 20130090616 | Neubauer | Apr 2013 | A1 |
| 20130102979 | Coulthard et al. | Apr 2013 | A1 |
| 20130138054 | Fleischmann | May 2013 | A1 |
| 20130150814 | Buan | Jun 2013 | A1 |
| 20130165878 | Heagle | Jun 2013 | A1 |
| 20130274688 | Weston | Oct 2013 | A1 |
| 20130296762 | Toth | Nov 2013 | A1 |
| 20130302545 | Schnelker et al. | Nov 2013 | A1 |
| 20130338614 | Heaton et al. | Dec 2013 | A1 |
| 20140114268 | Auguste et al. | Apr 2014 | A1 |
| 20140155849 | Heaton et al. | Jun 2014 | A1 |
| 20140228791 | Hartwell | Aug 2014 | A1 |
| 20140236109 | Greener | Aug 2014 | A1 |
| 20140309601 | Hall et al. | Oct 2014 | A1 |
| 20150065965 | Haggstrom et al. | Mar 2015 | A1 |
| 20150209492 | Blott et al. | Jul 2015 | A1 |
| 20150320604 | Adie et al. | Nov 2015 | A1 |
| 20160051737 | Joshi et al. | Feb 2016 | A1 |
| 20160081859 | Hartwell | Mar 2016 | A1 |
| 20160317357 | Vitaris et al. | Nov 2016 | A1 |
| 20160354086 | Dunn | Dec 2016 | A1 |
| 20170095598 | Joshi et al. | Apr 2017 | A1 |
| 20170128642 | Buan | May 2017 | A1 |
| 20170181896 | Hartwell | Jun 2017 | A1 |
| 20170181897 | Hartwell | Jun 2017 | A1 |
| 20170312407 | Coulthard et al. | Nov 2017 | A1 |
| 20180147091 | Greener et al. | May 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 2015201022 | Sep 2016 | AU |
| 2 705 898 | May 2009 | CA |
| 2 653 146 | Sep 2009 | CA |
| 2 739 243 | Apr 2010 | CA |
| 101385887 | Mar 2009 | CN |
| 847475 | Aug 1952 | DE |
| 3 137 839 | Mar 1983 | DE |
| 3 032 092 | Oct 1984 | DE |
| 34 43 101 | May 1986 | DE |
| 3 935 818 | May 1991 | DE |
| 4 012 232 | Oct 1991 | DE |
| 90 17 289 | Apr 1992 | DE |
| 19700271 | Sep 1997 | DE |
| 198 44 355 | Apr 2000 | DE |
| 20 2004 017 052 | Jul 2005 | DE |
| 0 020 662 | Jul 1984 | EP |
| 0 257 916 | Mar 1988 | EP |
| 0 340 018 | Nov 1989 | EP |
| 0 355 186 | Feb 1990 | EP |
| 0 521 434 | Jan 1993 | EP |
| 0 541 251 | May 1993 | EP |
| 0 617 152 | Sep 1994 | EP |
| 0 619 105 | Oct 1994 | EP |
| 0 858 810 | Aug 1998 | EP |
| 0 777 504 | Oct 1998 | EP |
| 0 888 141 | Jan 1999 | EP |
| 0 782 421 | Jul 1999 | EP |
| 0 941 726 | Sep 1999 | EP |
| 1 068 451 | Oct 1999 | EP |
| 1 007 015 | Jun 2000 | EP |
| 1 013 290 | Jun 2000 | EP |
| 1 029 585 | Aug 2000 | EP |
| 1 169 071 | Oct 2000 | EP |
| 1 105 171 | Jun 2001 | EP |
| 1 105 180 | Jun 2001 | EP |
| 1 107 813 | Jun 2001 | EP |
| 1 411 874 | Jul 2001 | EP |
| 1 030 657 | Oct 2001 | EP |
| 1 283 702 | Nov 2001 | EP |
| 1 339 366 | Jun 2002 | EP |
| 1 897 569 | Aug 2002 | EP |
| 0 708 620 | May 2003 | EP |
| 1 306 123 | May 2003 | EP |
| 1 088 569 | Aug 2003 | EP |
| 1 565 219 | Dec 2003 | EP |
| 1 440 737 | Jul 2004 | EP |
| 1 578 477 | Jul 2004 | EP |
| 1 018 967 | Aug 2004 | EP |
| 1 452 156 | Sep 2004 | EP |
| 1 440 667 | Mar 2006 | EP |
| 1 637 088 | Mar 2006 | EP |
| 1 284 777 | Apr 2006 | EP |
| 1 807 032 | May 2006 | EP |
| 1 263 366 | Jul 2006 | EP |
| 0 982 015 | Aug 2006 | EP |
| 1 923 077 | Nov 2006 | EP |
| 1 904 137 | Jan 2007 | EP |
| 1 448 261 | Feb 2007 | EP |
| 1 171 065 | Mar 2007 | EP |
| 1 922 045 | Mar 2007 | EP |
| 1 931 413 | Apr 2007 | EP |
| 1 880 840 | Jan 2008 | EP |
| 2 059 204 | Jan 2008 | EP |
| 1 476 217 | Mar 2008 | EP |
| 2 079 507 | Apr 2008 | EP |
| 2 106 255 | Jul 2008 | EP |
| 1 955 887 | Aug 2008 | EP |
| 2 109 472 | Aug 2008 | EP |
| 1 985 270 | Oct 2008 | EP |
| 1 121 163 | Nov 2008 | EP |
| 2 185 206 | Jan 2009 | EP |
| 2 178 573 | Feb 2009 | EP |
| 2 079 507 | Jul 2009 | EP |
| 2 098 257 | Sep 2009 | EP |
| 2 244 746 | Sep 2009 | EP |
| 2 254 537 | Sep 2009 | EP |
| 2 111 804 | Oct 2009 | EP |
| 2140968 | Jan 2010 | EP |
| 2 161 011 | Mar 2010 | EP |
| 2 326 295 | Mar 2010 | EP |
| 2 172 164 | Apr 2010 | EP |
| 1 807 031 | Jul 2010 | EP |
| 2 203 137 | Jul 2010 | EP |
| 2 253 353 | Nov 2010 | EP |
| 2 004 116 | Jun 2011 | EP |
| 2 335 749 | Jun 2011 | EP |
| 2 349 155 | Aug 2011 | EP |
| 2 420 214 | Feb 2012 | EP |
| 2 021 046 | Mar 2012 | EP |
| 2 462 908 | Jun 2012 | EP |
| 2 021 047 | Oct 2013 | EP |
| 2 711 034 | Mar 2014 | EP |
| 2 305 325 | Apr 2014 | EP |
| 2 345 437 | Apr 2014 | EP |
| 2 544 642 | Jan 2015 | EP |
| 2 648 668 | Jan 2015 | EP |
| 2 931 197 | Oct 2015 | EP |
| 2 687 245 | Feb 2016 | EP |
| 3 085 344 | Oct 2016 | EP |
| 3 139 878 | Mar 2017 | EP |
| 1 163 907 | Oct 1958 | FR |
| 114754 | Apr 1918 | GB |
| 236350 | Jul 1925 | GB |
| 641061 | Aug 1950 | GB |
| 821959 | Oct 1959 | GB |
| 1224009 | Mar 1971 | GB |
| 1255395 | Dec 1971 | GB |
| 1400124 | Jul 1975 | GB |
| 1549756 | Aug 1979 | GB |
| 2099306 | Dec 1982 | GB |
| 2195255 | Apr 1988 | GB |
| 2288734 | Nov 1995 | GB |
| 2307180 | May 1997 | GB |
| 2378392 | Feb 2003 | GB |
| 2415908 | Jan 2006 | GB |
| 2424582 | Oct 2006 | GB |
| 2435419 | Feb 2007 | GB |
| 2435422 | Aug 2007 | GB |
| 59-87824 | Jun 1984 | JP |
| H02-139624 | Nov 1990 | JP |
| H09-505752 | Jun 1997 | JP |
| 2001-011759 | Jan 2001 | JP |
| 2003-165843 | Jun 2003 | JP |
| 2003-250879 | Sep 2003 | JP |
| 2003-532504 | Nov 2003 | JP |
| 2004-509658 | Apr 2004 | JP |
| 2009-506878 | Feb 2009 | JP |
| 2009-509570 | Mar 2009 | JP |
| 2009-536852 | Oct 2009 | JP |
| 2010-504816 | Feb 2010 | JP |
| 2010-516387 | May 2010 | JP |
| 2014-518651 | Mar 2014 | JP |
| 1251912 | Apr 1983 | SU |
| WO 198300742 | Mar 1983 | WO |
| WO 198401904 | May 1984 | WO |
| WO 199011795 | Oct 1990 | WO |
| WO 199100718 | Jan 1991 | WO |
| WO 1992009301 | Jun 1992 | WO |
| WO 199209651 | Jun 1992 | WO |
| WO 199220299 | Nov 1992 | WO |
| WO 199306802 | Apr 1993 | WO |
| WO 199309176 | May 1993 | WO |
| WO 1994020133 | Sep 1994 | WO |
| WO 199423677 | Oct 1994 | WO |
| WO 199504511 | Feb 1995 | WO |
| WO 199514451 | Jun 1995 | WO |
| WO 199516416 | Jun 1995 | WO |
| WO 1995029959 | Nov 1995 | WO |
| WO 199605873 | Feb 1996 | WO |
| WO 199621410 | Jul 1996 | WO |
| WO 199640174 | Dec 1996 | WO |
| WO 199703717 | Feb 1997 | WO |
| WO 199711658 | Apr 1997 | WO |
| WO 199733922 | Sep 1997 | WO |
| WO 199742986 | Nov 1997 | WO |
| WO 199803267 | Jan 1998 | WO |
| WO 199806444 | Feb 1998 | WO |
| WO 199901173 | Jan 1999 | WO |
| WO 199917698 | Apr 1999 | WO |
| WO 199930629 | Jun 1999 | WO |
| WO 199939671 | Aug 1999 | WO |
| WO 1999047097 | Sep 1999 | WO |
| WO 199965536 | Dec 1999 | WO |
| WO 2000007653 | Feb 2000 | WO |
| WO 200038752 | Jul 2000 | WO |
| WO 200042957 | Jul 2000 | WO |
| WO 200050143 | Aug 2000 | WO |
| WO 200059424 | Oct 2000 | WO |
| WO 200061206 | Oct 2000 | WO |
| WO 200062827 | Oct 2000 | WO |
| WO 2000064396 | Nov 2000 | WO |
| WO 200119430 | Mar 2001 | WO |
| WO 200134223 | May 2001 | WO |
| WO 2001062312 | Aug 2001 | WO |
| WO 2001066017 | Sep 2001 | WO |
| WO 2001085248 | Nov 2001 | WO |
| WO 200202079 | Jan 2002 | WO |
| WO 200217840 | Mar 2002 | WO |
| WO 200226180 | Apr 2002 | WO |
| WO 200238096 | May 2002 | WO |
| WO 2002076379 | Oct 2002 | WO |
| WO 2002083046 | Oct 2002 | WO |
| WO 2002092783 | Nov 2002 | WO |
| WO 2002094256 | Nov 2002 | WO |
| WO 2002102864 | Dec 2002 | WO |
| WO 2003045492 | Jun 2003 | WO |
| WO 2003057307 | Jul 2003 | WO |
| WO 2003092620 | Nov 2003 | WO |
| WO 2004024300 | Mar 2004 | WO |
| WO 2004037334 | May 2004 | WO |
| WO 2004054632 | Jul 2004 | WO |
| WO 2004073566 | Sep 2004 | WO |
| WO 2004077387 | Sep 2004 | WO |
| WO 2005009488 | Feb 2005 | WO |
| WO 2005016179 | Feb 2005 | WO |
| WO 2005017000 | Feb 2005 | WO |
| WO 2005018695 | Mar 2005 | WO |
| WO 2005025447 | Mar 2005 | WO |
| WO 2005025666 | Mar 2005 | WO |
| WO 2005046761 | May 2005 | WO |
| WO 2005051461 | Jun 2005 | WO |
| WO 2005070480 | Aug 2005 | WO |
| WO 2005082435 | Sep 2005 | WO |
| WO 2005105180 | Nov 2005 | WO |
| WO 2005118011 | Dec 2005 | WO |
| WO 2005123170 | Dec 2005 | WO |
| WO 2006014534 | Feb 2006 | WO |
| WO 2006030054 | Mar 2006 | WO |
| WO 2006034128 | Mar 2006 | WO |
| WO 2006048246 | May 2006 | WO |
| WO 2006052745 | May 2006 | WO |
| WO 2006052839 | May 2006 | WO |
| WO 2006056294 | Jun 2006 | WO |
| WO 2006081403 | Aug 2006 | WO |
| WO 2006087021 | Aug 2006 | WO |
| WO 2006116992 | Nov 2006 | WO |
| WO 2006135506 | Dec 2006 | WO |
| WO 2007002835 | Jan 2007 | WO |
| WO 2007013064 | Feb 2007 | WO |
| WO 2007019038 | Feb 2007 | WO |
| WO 2007024230 | Mar 2007 | WO |
| WO 2007030598 | Mar 2007 | WO |
| WO 2007030601 | Mar 2007 | WO |
| WO-2007059742 | May 2007 | WO |
| WO 2007084792 | Jul 2007 | WO |
| WO 2007085396 | Aug 2007 | WO |
| WO 2007092397 | Aug 2007 | WO |
| WO 2007106592 | Sep 2007 | WO |
| WO 2007106594 | Sep 2007 | WO |
| WO 2007124198 | Nov 2007 | WO |
| WO 2007133618 | Nov 2007 | WO |
| WO 2008013896 | Jan 2008 | WO |
| WO 2008027449 | Mar 2008 | WO |
| WO 2008039223 | Apr 2008 | WO |
| WO 2008039314 | Apr 2008 | WO |
| WO 2008039839 | Apr 2008 | WO |
| WO 2008040020 | Apr 2008 | WO |
| WO 2008041926 | Apr 2008 | WO |
| WO 2008049277 | May 2008 | WO |
| WO 2008064502 | Jun 2008 | WO |
| WO 2008076407 | Jun 2008 | WO |
| WO 2008082444 | Jul 2008 | WO |
| WO 2008100437 | Aug 2008 | WO |
| WO 2008100440 | Aug 2008 | WO |
| WO 2008104609 | Sep 2008 | WO |
| WO 2008112304 | Sep 2008 | WO |
| WO 2008131895 | Nov 2008 | WO |
| WO 2008134544 | Nov 2008 | WO |
| WO 2008134774 | Nov 2008 | WO |
| WO 2009002260 | Dec 2008 | WO |
| WO 2009019227 | Feb 2009 | WO |
| WO 2009019229 | Feb 2009 | WO |
| WO 2009021523 | Feb 2009 | WO |
| WO 2009042514 | Apr 2009 | WO |
| WO 2009047524 | Apr 2009 | WO |
| WO 2009052193 | Apr 2009 | WO |
| WO 2009060327 | May 2009 | WO |
| WO 2009062327 | May 2009 | WO |
| WO 2009066104 | May 2009 | WO |
| WO 2009066105 | May 2009 | WO |
| WO 2009066106 | May 2009 | WO |
| WO 2009071932 | Jun 2009 | WO |
| WO 2009089390 | Jul 2009 | WO |
| WO 2009097534 | Aug 2009 | WO |
| WO 2009103031 | Aug 2009 | WO |
| WO 2009111655 | Sep 2009 | WO |
| WO 2009111657 | Sep 2009 | WO |
| WO 2009114790 | Sep 2009 | WO |
| WO 2009117635 | Sep 2009 | WO |
| WO 2009122989 | Oct 2009 | WO |
| WO 2009124100 | Oct 2009 | WO |
| WO 2009124125 | Oct 2009 | WO |
| WO 2009126102 | Oct 2009 | WO |
| WO 2009126103 | Oct 2009 | WO |
| WO 2009126833 | Oct 2009 | WO |
| WO 2009146441 | Dec 2009 | WO |
| WO 2009151380 | Dec 2009 | WO |
| WO 2009156709 | Dec 2009 | WO |
| WO 2009158124 | Dec 2009 | WO |
| WO 2009158127 | Dec 2009 | WO |
| WO 2009158128 | Dec 2009 | WO |
| WO 2009158130 | Dec 2009 | WO |
| WO 2010008167 | Jan 2010 | WO |
| WO 2010026251 | Mar 2010 | WO |
| WO 2010033574 | Mar 2010 | WO |
| WO 2010033613 | Mar 2010 | WO |
| WO 2010035017 | Apr 2010 | WO |
| WO 2010051418 | May 2010 | WO |
| WO 2010059849 | May 2010 | WO |
| WO 2010072309 | Jul 2010 | WO |
| WO 2010072395 | Jul 2010 | WO |
| WO 2010082872 | Jul 2010 | WO |
| WO 2010089448 | Aug 2010 | WO |
| WO 2010120776 | Oct 2010 | WO |
| WO 2010139926 | Dec 2010 | WO |
| WO 2010141271 | Dec 2010 | WO |
| WO 2010142959 | Dec 2010 | WO |
| WO 2010147533 | Dec 2010 | WO |
| WO 2010147592 | Dec 2010 | WO |
| WO 2011019476 | Feb 2011 | WO |
| WO 2011023275 | Mar 2011 | WO |
| WO 2011023650 | Mar 2011 | WO |
| WO 2011115908 | Sep 2011 | WO |
| WO 2011128651 | Oct 2011 | WO |
| WO 2011135284 | Nov 2011 | WO |
| WO 2011135285 | Nov 2011 | WO |
| WO 2011135286 | Nov 2011 | WO |
| WO 2011135287 | Nov 2011 | WO |
| WO 2011144888 | Nov 2011 | WO |
| WO 2012009370 | Jan 2012 | WO |
| WO 2012022484 | Feb 2012 | WO |
| WO 2012028842 | Mar 2012 | WO |
| WO 2012041296 | Apr 2012 | WO |
| WO 2012074512 | Jun 2012 | WO |
| WO 2012131237 | Oct 2012 | WO |
| WO 2012140378 | Oct 2012 | WO |
| WO 2012143665 | Oct 2012 | WO |
| WO 2012146656 | Nov 2012 | WO |
| WO 2012150235 | Nov 2012 | WO |
| WO 2015172108 | Nov 2015 | WO |
| Entry |
|---|
| “Technology Watch”, May 1989, in 1 page. |
| Achterberg, V. et al., “Hydroactive dressings and serum proteins: an in vitro study”, Journal of Wound Care, February, vol. 5, No. 2, 1996, pp. 79-82, in 4 pages. |
| Argenta, L. et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment; Clinical Experience”, Ann Plas Surg, Jun. 1997; vol. 38, pp. 563-577 (Dec. 10, 1996). |
| Aubrey, D.A., et al., “Treatment of the Perineal Wound after Proctectomy by Intermittent Irrigation”, Arch. Surg., vol. 119, Oct. 1984, pp. 1141-1144, in 4 pages. |
| Bagautdinov, N.A., “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues”, in Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye. Volkov et al. (Chuvash State University, Cheboksary, USSR 1986) pp. 94-96. |
| Bevan, D. et al., “Diverse and potent activities of HGF/SF in skin wound repair”, Journal of Pathology, vol. 203, 2004, pp. 831-838, in 8 pages. |
| Canadian Office Action, re CA Application No. 2,739,605, dated Aug. 22, 2011. |
| Chariker, M.E. et al., “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction Wound Drainage”, Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63, in 5 pages. |
| Chintamani, V. et al., “Half versus full vacuum suction drainage after modified radical mastectomy for breast cancer—a prospective randomized clinical trial”, Research Article (Jan. 27, 2005), pp. 1-5, in 5 pages. |
| Communication of Notice of Opposition dated Dec. 17, 2015, and Opposition of European patent EP 2 563 308 B1, dated Dec. 11, 2015, on behalf of KCI Licensing, Inc., and cited publications D1-D6, in 250 pages. |
| Davydov, Yu A., et al., “Concepts for Clinical Biological Management of the Wound Process in the Treatment of Purulent Wounds Using Vacuum Therapy”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 15-17. |
| Davydov, Yu A., et al., “The Bacteriological and Cytological Assessment of Vacuum Therapy of Purulent Wounds”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 11-14, in 4 pages. |
| Davydov, Yu A., et al., “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 5-7. |
| Declaration of Chris Locke submitted in the Opposition against European Patent No. EP 2 563 308, dated Sep. 7, 2016, in 6 pages. |
| De Lange, M.Y. et al., “Vacuum-Assisted Closure: Indications and Clinical Experience”, Eur J Plast Surg vol. 23, 2000, pp. 178-182 (Feb. 9, 2000), in 5 pages. |
| Dilmaghani, A. et al., “A Method for Closed Irrigation and Suction Therapy in Deep Wound Infections,” Journal of Bone and Joint Surgery, 1969, vol. 51-A, No. 2, pp. 323-342, in 20 pages. |
| English Translation of Invalidity Suit by KCI Medizinprodukte GmbH versus Kalypto Medical, Inc., concerning declaration of invalidity of the German part of the European Patent No. 2 021 046 (German application No. 60 2007 021 330.4) dated Mar. 11, 2015 in 38 pages. EP 2 021 046 is related to the present application by virtue of a common priority claim to U.S. Appl. No. 11/432,855, now U.S. Pat. No. 7,615,036, and U. S. Appl. No. 11/610,458, now U.S. Pat. No. 7,779,625. |
| Hartz, R.S. et al., “Healing of the Perineal Wound”, Arch. Surg., Apr. 1980, vol. 115, pp. 471-474, in 4 pages. |
| Health Technology, Literature R., “Vacuum Assisted Closure Therapy for Wound Care”, Health Technology Literature Review, Dec. 2004, pp. 3-59, in 57 pages. |
| Hersle, K. et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies”, The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, in 4 pages. |
| International Search Report, re PCT Application No. PCT/GB2008/051088, dated Mar. 4, 2009. |
| International Search Report, re PCT Application No. PCT/GB2008/051090, dated Mar. 4, 2009. |
| International Search Report, re PCT Application No. PCT/GB2008/051089, dated Mar. 4, 2009. |
| International Search Report for International Application No. PCT/GB2011/000622, dated Jul. 28, 2011. |
| International Search Report for International Application No. PCT/GB2011/000625, dated Aug. 10, 2011 in 5 pages. |
| International Search Report for PCT Application No. PCT/GB2011/000626, dated Aug. 4, 2011. |
| International Search Report for PCT Application No. PCT/GB2011/000628, dated Sep. 6, 2012. |
| International Search Report for International Application No. PCT/GB2011/000621, dated Jul. 26, 2011. |
| International Search Report for International Application No. PCT/GB2011/000629, dated Dec. 23, 2011. |
| Kalypto Medical, NPD 1000 Negative Pressure Wound Care System, Clinician & Patient Instructions for Use (publication date unknown, believed to be Feb. 2010), in 36 pages. |
| Kalypto Medical, NPD 1000 Product Brochure (publication date unknown, believed to be Nov. 2010), in 4 pages. |
| Kendall ULTEC Hydrocolloid Dressing (4″×4″), product ordering page, web page downloaded Jul. 13, 2014, in 1 page. |
| The Kremlin Papers, “A Collection of Published Studies Complementing the Research and Innovation of Wound Care”, The Kremlin Papers—Perspectives in Wound Care, Russian Medical Journal, Vestnik Khirurgii, Blue Sky Publishing (2004), pp. 2-17, in 17 pages. |
| Kostiuchenok, B. M. et al., “The Vacuum Effect in the Surgical Treatment of Purulent Wounds”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California, 2004, pp. 3-4 (English translation only). |
| Advantec MFS, Inc., “Membrane Filters” (catalog), accessed Jan. 29, 2016 (publication date unknown, but believed to be copyright 2001-2011), in 17 pages. URL: http://www.advantecmfs.com/catalog/filt/membrane.pdf#page=11. |
| Mitchell, R. et al., “Role of Stem Cells in Tissue Homeostasis”, Pocket Companion to Robbins and Cotran Pathologic Basis of Disease, 7th Edition, 2006, in 3 pages. |
| Morykwas, M. J., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997) 553-562, in 10 pages. |
| Nursing75, “Wound Suction: Better Drainage with Fewer Problems”, Nursing, vol. 5, No. 10, Oct. 1975, pp. 52-55, in 4 pages. |
| Prevena™ Incision Management System, Clinician Guide, pp. 1-9, Jan. 2010, in 10 pages. |
| Prevena™ Incision Management System, Patient Guide, pp. 1-2, Jan. 2010, in 4 pages. |
| Protz, Kerstin: “Moderne Wundauflagen unterstutzen Heilungsprozess”, Wundversorgung: Indikation und Anwendung, Geriatrie Journal, Apr. 2005, pp. 3333-3339, with translation, in 17 pages. |
| Reply to Appeal, in Opposition by KCI Licensing Inc. to Smith & Nephew PLC, re European Patent No. 2 563 308, dated May 24, 2018, in 9 pages. |
| Reply to Grounds of Appeal, in Opposition by KCI Licensing Inc. to Smith & Nephew PLC, re European Patent No. 2 563 308, dated Apr. 27, 2018, in 4 pages. |
| Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System”, spiral booklet, Mar. 2011, in 7 pages. |
| Solovev, V. A., et al., “The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract—Guidelines” USSR Ministry of Health, S. M. Kirov Gorky State Medical Institute, 1987 (with English translation). |
| Solovev, V.A. “Treatment and Prevention of Suture Failures after Gastric Resection” (Dissertation Abstract) (S.M. Kirov Gorky State Medical Institute, Gorky USSR 1988). |
| Stewart, J., “World Wide Wounds—Next Generation of Products for Wound Management”, 2002, in 13 pages. |
| Svedman, P., “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers,” Scand J. Plast. Reconstr. Surg., 19:211-213, 1985. |
| Svedman, P. “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 1983, pp. 532-534, in 3 pages. |
| Svedman, P., “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Med. Science: Biomed. Tech.; Clinic. Med.; Surg. and Transplantation, 1979, vol. 7, p. 221, in 1 page. |
| Svedman, P. et al., “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133, in 9 pages. |
| Swift, S. et al, “Quorum Sensing in Aeromonas hydrophila and Aeromonas salmonicida: Identification of LuxRI Homologs AhyRI and AsaRI and Their Cognate N-Acylhomoserine Lactone Signal Molecules,” J. Bacteriol., 1997, vol. 179(17), pp. 5271-5281, in 12 pages. |
| Teder, H. et al., “Continuous Wound Irrigation in the Pig,” Journal of Investigative Surgery, vol. 3, 1990, pp. 399-407, in 9 pages. |
| The American Heritage Dictionary of the English Language, Fourth Edition, 2000. |
| Tribble, D. E., “An Improved Sump Drain-Irrigation Device of Simple Construction”, Archives of Surgery New York, vol. 105, Sep. 1972, in 4 pages. |
| Usupov, Y. N., et al., “Active Wound Drainage”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), pp. 8-10. |
| Venturi, M. et al., “Mechanisms and Clinical Applications of the Vacuum-Assisted Closure (VAC) Device”, Am J Clin Dermatol (2005) 693, pp. 185-194; Review Article (2005), pp. 185-194, in 10 pages. |
| Vijanto, J. and J. Raekallio, Local Hyperalimentation of Open Wounds, Br. J. surg., 1976, 63, 427-430. |
| Webb, L., “New Techniques in Wound Management: Vacuum-Assisted Wound Closure”, Journal of the American Academy of Orthopedic Surgeons, vol. 10, No. 5, Sep. 2002, pp. 303-311, in 9 pages. |
| Westaby, S. et al., “A Wound Irrigation Device”, The Lancet, Sep. 2, 1978, pp. 503-504, in 2 pages. |
| Wooding-Scott, M. et al., “No Wound is Too Big for Resourceful Nurses,” RN, Dec. 1988, pp. 22-25, USA, in 4 pages. |
| Wound Suction, Nursing, Oct. 1975, USA pp. 52-53. |
| Grounds for the Decision, re the Opposition of European Patent No. EP 2 563 306, dated Sep. 7, 2018, in 101 pages. |
| Reply to the Appeal, re the Opposition of European Patent No. EP 2 563 306, dated May 21, 2019, in 18 pages. |
| Statement of Grounds of Appeal, re the Opposition of European Patent No. EP 2 563 306, dated Jan. 16, 2019, in 90 pages. |
| Data Sheet for the decision for Jul. 17, 2020 cited during the appeal procedure for European Patent No. 2563308, mailed on Jan. 22, 2021, 37 pages. |
| Declaration of Chris Locke in support of the opposition to European Patent No. 2563308 dated Sep. 7, 2016, 1 page. |
| Letter of the Patent Proprietor dated Jan. 22, 2021 relating to the appeal procedure for European Patent No. 2563308, 9 pages. |
| Brief Communication of Letter from the proprietor of the patent and copies of Auxiliary requests 1-2 for European Patent No. 2821035 mailed on Feb. 12, 2021, 27 pages. |
| Letter of the opponent relating to oral proceedings during the appeal procedure for European Patent No. 2563308, mailed on Feb. 26, 2021, 3 pages. |
| Annex to the Communication, the Opposition of European Patent No. 2563306, mailed on Oct. 6, 2017, 15 pages. |
| Information about the Result of Oral Proceedings for the Opposition of European Patent No. EP2563306, dated Jun. 21, 2018, 1 page. |
| Information about the Result of Oral Proceedings for the Opposition of European Patent No. EP2563308, dated Jul. 21, 2017, 3 pages. |
| Interlocutory Decision and Annex to the Communication for the Opposition of European Patent No. EP2563308, dated Aug. 14, 2017, 76 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2011/000622, dated Nov. 8, 2012, 7 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2011/000625, dated Nov. 8, 2012, 8 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2011/000626, dated Nov. 8, 2012, 8 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2011/000628, dated Nov. 8, 2012, 8 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2011/000629, dated Oct. 31, 2013, 8 pages. |
| International Preliminary Report on Patentability for Application No. PCT/GB2011/00621, dated Nov. 29, 2012, 7 pages. |
| Letter regarding the Opposition Procedure from the Opponent for the Opposition of European Patent No. 2563308, dated Nov. 10, 2016, 10 pages. |
| Letter relating to the Appeal Procedure for the Opposition of the European Patent No. 2563306, mailed on Jan. 17, 2019, 3 pages. |
| Letter relating to the Appeal Procedure for the Opposition of the European Patent No. 2563308, mailed on Apr. 17, 2018, in 6 pages. |
| Letter relating to the Appeal Procedure for the Opposition of the European Patent No. 2563308, mailed on Jun. 22, 2018, in 4 pages. |
| Macmillan Dictionary, “Comprise,” Retrieved from https://www.macmillandictionary.com/us/dictionary/american/comprise on Jan. 29, 2020, 4 pages. |
| Merriam-Webster, “Comprise,” Retrieved from https://www.merriam-webster.com/dictionary/comprise on Jan. 29, 2020, 8 pages. |
| Notice of Appeal by Appellant for the Opposition of the European Patent No. 2563308, mailed on Oct. 9, 2017, 4 pages. |
| Notice of Appeal by Proprietor for the Opposition of the European Patent No. 2563308, mailed on Oct. 10, 2017, 5 pages. |
| Notice of Opposition—Opponent's Statement of Facts and Arguments for the European Patent No. 2821035, mailed on Sep. 7, 2020, 12 pages. |
| Notice of Opposition—Statement of Facts and Evidence for the European Patent No. 2563306, mailed on Dec. 30, 2016, 19 pages. |
| Notice of Oppositions from Opponent for the European Patent No. 2821035, mailed on Sep. 8, 2020, 73 pages. |
| Opponent's letter relating to the Appeal Procedure for the Opposition of the European Patent No. 2563306, mailed on Aug. 2020, 37 pages. |
| Opponent's Written Submission in Preparation for the Oral Proceedings for the Opposition of European Patent No. 2563308, mailed on May 19, 2017, 10 pages. |
| Opponent's Written Submission in Preparation for the Oral Proceedings for the Opposition of European Patent No. EP2563306, dated Apr. 20, 2018, 14 pages. |
| Opponent's Written Submission in Preparation for the Oral Proceedings for the Opposition of European Patent No. EP2563306, dated Jun. 11, 2018, 7 pages. |
| Preparation for Oral Proceedings and Annex to the Communication for the Opposition of European Patent No. 2563308, mailed on Dec. 19, 2016, 18 pages. |
| Priority Document filed Apr. 27, 2010 for Great Britain Application No. 1006986.2, by Smith & Nephew PLC, 40 pages. |
| Proprietor's letter relating to the Appeal Procedure for the Opposition of the European Patent No. 2563306, mailed on Aug. 6, 2020, 32 pages. |
| Proprietor's Written Submission in Preparation for the Oral Proceedings, the Opposition of European Patent No. 2563306, mailed on Apr. 19, 2018, 39 pages. |
| Proprietor's Written Submission in Preparation for the Oral Proceedings, the Opposition of European Patent No. 2563308, mailed on Jul. 10, 2017, 12 pages. |
| Proprietor's Written Submission in Preparation for the Oral Proceedings, the Opposition of European Patent No. 2563308, mailed on May 17, 2017, 37 pages. |
| Reply of the Patent Proprietor to the Notice of Opposition for the European Patent No. 2563306, mailed on Jun. 5, 2017, 44 pages. |
| Reply of the Patent Proprietor to the Notice of Opposition for the European Patent No. 2563308, mailed on Aug. 15, 2016, 35 pages. |
| Specification and drawings filed in application No. EP14187266.3, file on Jan. 8, 2010, 46 pages. |
| Statement of Grounds of Appeal by Appellant for the Opposition of European Patent No. 2563308, dated Dec. 12, 2017, 6 pages. |
| Statement of Grounds of Appeal by Appellant-Proprietor for the Opposition of European Patent No. 2563308, mailed on Dec. 5, 2017, 26 pages. |
| Declaration of Chris Locke Submitted in the Opposition against European Patent No. 2231221, mailed on Sep. 7, 2016, 1 page. |
| Merriam-Webster, Definition of “Port”, retrieved from URL: https://www.merriam-webster.com/dictionary/port, on Oct. 26, 2020, 6 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20190008690 A1 | Jan 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15633670 | Jun 2017 | US |
| Child | 16118352 | US | |
| Parent | 14715399 | May 2015 | US |
| Child | 15633670 | US | |
| Parent | 13092042 | Apr 2011 | US |
| Child | 14715399 | US |
